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Chapter I 
INTRODUCTION AND PROBLEM STATEMENT 
9 
Replacement of kidneys v/hich have irreversibly lost their 
function is now a generally accepted form of treatment. The main 
technical and surgical problems in kidney transplantation have 
been solved. However, five year survival rates of transplanted 
kidneys in centres participating in the Eurotransplant Organiza­
tion are still not higher than 39.6% if there is a four antigen 
mismatch and 56.6% if there are no HLA-A and В mismatches (Euro-
transplant Annual Report, 1977). The majority of losses is caused 
by rejection of the graft. 
After transplantation a dual response can occur which may lead 
to rejection. The first type of response is mediated by specifi­
cally activated cytotoxic Τ cells. It most often occurs within 
a few days after transplantation, and leads to a so-called 
cellular rejection of acute onset. In many instances this type of 
rejection can be treated with success by increasing the dose of 
immunosuppressive drugs. The second type of rejection is mediated 
by antibodies specifically directed against the donor antigens. 
These antibodies, if complexed with the antigens toward which 
they are directed,can trigger a number of effector systems, which 
can cause the eventual damage of the graft. One of the important 
inflammatory effector systems triggered by antigen-antibody com­
plexes is the complement sequence. The humoral type of rejection 
has in most instances an insidious onset and responds very poorly 
to immunosuppressive treatment. It therefore accounts for a con­
siderable amount of graft losses. There exists a host of informa­
tion concerning the pathogenic significance of humoral anti-donor 
responses for the ultimate fate of the graft (reviewed by Carpen­
ter et al, 1976). Anti-donor antibodies in the complement dependent 
cytotoxicity assay or a positive antibody dependent lymphocyto-
toxicity were found during rejection episodes in almost 100% of 
the cases (Stiller et al, 1976; Gailiunas et al, 1978). Histologic 
examinations of grafts removed after chronic rejection show 
intimai proliferation and media thickening (Kincaid-Smith, 196 7; 
Busch et al, 1969), associated with deposition of IgG on the 
vascular endothelium and in the tunica media (Busch et al, 1971). 
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The development of these lesions is associated with circulating 
anti-donor antibodies (Jeannet et al, 19 70). The anti-donor 
antibodies are not always detectable in the circulation, but this 
can not serve as an argument against humorally mediated rejection, 
because the antibodies formed can to a great extent be absorbed 
by the graft. In these cases they are only detectable in the 
circulation after removal of the grafted kidney (Milgrom, 1977) . 
The most ideal approach to improve the results of human renal 
allografting is the prevention of the above mentioned rejection 
responses in the recipient by complete matching for the antigens 
coded for by the major histocompatibility complex. This has been 
done most successfully in the transplantation of kidneys from 
living, МНС-identical sibling donors. In such donor-recipient 
combinations graft survival rates between 90 - 100% have been 
achieved. However, in cadaveric kidney transplantation complete 
compatibility between donor and recipient is very rare because 
of the great polymorphism of the МНС-system and the presence of 
hitherto unidentified transplantation loci. This problem of 
graft rejection calls for a continuing search for better and less 
toxic forms of immunosuppression. The recently discovered strong 
immunosuppressive activity of cyclosporin A might open new possi­
bilities in this area (Borei et al, 1977; Green and Allison, 
1978; Calne et al, 1978a> 1978b). In the humoral rejection process 
the destructive effects of formed anti-donor antibodies might be 
prevented by manipulating the host's complement system. There 
exists a great deal of evidence in the literature that complement 
participates in humoral graft rejection, especially in human 
renal allografting. The literature concerning this aspect is dis­
cussed in one of the subsequent sections (chapter III). 
Before complement inhibition can become applicable we must 
have a better understanding of the fundamental mechanisms that 
are operative in this humoral rejection process. In 19 73 an ex­
perimental animal model was developed in our laboratory in which 
antibody-mediated destruction could be reproducibly elicited 
(Koene et al, 1973). The model was based on previous studies in 
which it was shown that mouse alloantisera are devoid of cyto­
toxic activity versus donor lymphoid cells if fresh mouse serum 
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is used as a complement source. Cytotoxicity becomes only apparent 
in the presence of guinea pig complement, and is highest with 
rabbit complement (Koene and McKenzie, 1973). Similarly, mouse 
skin allografts could not be destroyed by injection of anti-donor 
antibodies. Acute antibody-mediated rejection (AAR) of established 
skin grafts in immunosuppressed mice could, however, be induced 
by the administration of anti-donor serum together with rabbit 
complement. Administration of exogenous complement was not in all 
donor-recipient combinations a prerequisite to induce antibody-
mediated destruction. Baldamus et al (1973) described a xeno-
geneic skin graft model, in which rat skin grafted onto immuno-
suppressed mice was destroyed by passive administration of mouse 
anti rat serum alone. The mouse endogenous complement was suffi-
ciently activated in this model, which was most likely a conse-
quence of the greater antigenic disparity. We, therefore, decided 
to investigate the influence of antigenic disparity on AAR in a 
number of graft experiments in strain combinations with increasing 
histoincompatibility. Because of the earlier mentioned differences 
in the cytolytic efficiency of different complement sources in 
lymphocytotoxicity assays their ability to mediate AAR in vivo 
was compared to their cytotoxicity in vitro with the same anti-
serum (chapter IV). 
From earlier experiments it was known that, if rabbit comple-
ment was inactivated prior to its administration along with anti-
serum, AAR did not occur (Gerlag, 1975) . This effect has now been 
studied in more detail and we have especially focused our attention 
on the question which complement factors were necessary for the 
induction of AAR. This was done by depleting the complement source 
in vitro of distinct complement factors prior to its administration 
and by the use of complement factor deficient sera. This approach 
can provide information at which level the complement sequence 
has to be inhibited in order to prevent AAR (chapter V). 
Although manipulation of an administered exogenous complement 
species can give fundamental insight into the mechanisms of AAR, 
it is indispensable to complete the information thus gained by 
studies of the endogenous complement system. Especially its con-
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sumption during AAR, and on the other hand the influence of in-
hibition of the complement sequence on AAR are important in this 
regard. For this purpose we used the xenogeneic skin graft model 
in the mouse, because in this system AAR is mediated by the en-
dogenous complement of the mouse (chapter VII). 
Before such a study was possible we had to develop a sensitive 
assay for the accurate measurements of mouse complement levels, 
since there was no method reported in the literature that had the 
desired sensitivity (chapter VI) . 
Prior to the presentation of the experimental data a review is 
given concerning the immunochemical sequences and immunobiological 
effects of the complement system. Special reference is given to 
certain complement deficiencies in animals since we used sera of 
these animals in a number of experiments (chapter II). 
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Chapter II 
THE COMPLEMENT SYSTEM 
17 
2.1. INTRODUCTION 
Complement is one of the major effector systems in the inflan-
matory and immunologic response. It consists of a number of 
proteins, present in serum in non-active precursor forms (Table 
1). Most of these obtain enzyme-like activity after activation, 
leading to a sequential interaction of the individual complement 
components. After activation by immunoglobulins, fungal or bac-
terial products, multimolecular assemblages are formed, prefer-
entially on the surface of biological membranes. This can lead 
to the alteration of the target complex, and, depending on the 
cell type involved, specialized cell functions are initiated 
such as histamine release, enhancement of phagocytosis, con-
traction of smooth muscles, aggregation and fusion of platelets. 
Alternatively, lysis of the cell membrane may occur with conse-
quent death of the target cell. Activated complement components 
released in the fluid phase can also induce alterations of the 
micro-environment such as Increased vascular permeability, and 
Chemotaxis. Furthermore, the complement system shows interactions 
with other plasma protein systems, e.g. the clotting sequence, 
the fibrinolytic system, and the kinm-generating system. 
The complement system is most conveniently divided into four 
parts. This is schematically illustrated in figure 1. There are 
two pathways for activation: the classical and alternative path-
way which both lead to the generation of a C3-convertase. The 
amplification loop is a positive feed-back cycle, in which 
generation of C3b promotes the activation of the alternative 
pathway. The terminal "attack" unit is a kind of final common 
pathway, which generates Chemotaxis and induces cell lysis. 
Spontaneous and generalized complement activation, with its 
potentially dangerous effects, is prevented by the rapid intrin-
sic decay of the formed enzymes and by the existence of several 
control proteins. Table 1 summarizes some characteristics of the 
various proteins involved in the complement system. The inrnmno-
chemistry and immunobiology of the various complement components 
will be discussed in more detail in the subsequent sections. 
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TABLE I. Physiooaherrtcal aharaoteristzos of proteins of the oorrplement system 
Approximate Electro- Serum Cleavage 
molecular phoretic concentration fragments 
weight(daltons) nobility (ug/ml) 
Classiaal pathway 
Clq 
Clr 
Cls 
C4 
C2 
Alternative pathuay 
Properdin 
Factor D (C3PAse)b 
390,000 
188,000 
86,000 
209,000 
117,000 
223,000 
25,000 
Factor В (C3PA,GBG)100,000 
C3 (BiO 185,000 
Ύ2 
6 
аг 
ei 
ß2 
Y2 
«2 
ß2 
Bi 
190 
100 
120 
430 
30 
25 
trace 
240 
1300 
C4a,C4b,C4c,C4d 
C2a,C2b(?C-kinin) 
Bb(C3A,GGG), 
Ba(GAG) 
CSajCSb.CScißjA) 
C3d(a2D) 
Initiating factor IF 
C3 nephritic factor 
C3NeF 
Attack sequence 
C5 
C6 
C7 
C8 
C9 
Control proteins 
cT. INH 
3iH 
C3b.INA(KAF) 
AI 
170,000 
160,000 
206,000 
95,000 
120,000 
153,000 
79,000 
105,000 
150,000 
100,000 
310,000 
6 
Y 
ei 
ß2 
ß2 
<n 
a 
<*2 
e 
ß2 
02 
? 
•p 
75 
60 
55 
40 
10 
180 
600 
25 
7 
C5a,C5b 
a) Modified, according to Fearon and Austen, 1976. 
b) Formerly used synonyms given between parentheses. 
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Figure 1. Schematic representation of the four functional parts 
of the complement system. 
2.2. NOMENCLATURE OF THE COMPLEMENT SYSTEM 
In 1968 a standard nomenclature for the classical complement 
sequence was chosen (Bull. WHO, 1968) to cope with the existing 
confusion in terminology (see synonyms table 1). The complement 
factors are notated by numbers in the same sequence as they 
react in immune hemolysis. Each number is preceded by the symbol 
C. For historical reasons an exception has been made for C4, 
giving the sequence: C1-C4-C2-C3-C5-C6-C7-C8-C9. The first com­
ponent CI comprises 3, possibly 4, distinct protein subcomponents 
named Clq-Clr-Cls (and probably Clt). If a component becomes 
activated, the activated state is denoted by a vertical bar over 
the number for example: cTs. The postscript "i" represents the 
inactive state of a previously active component (e.g. C2i) . 
If a component is cleaved the postscript "a" is used for the 
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smaller fragment, and the postscript "b" for the bigger one 
(C3a-C3b). C3b and C4b further cleave into two fragments each, 
which are denoted as C3c-C3d and C4c-C4d. The factors involved 
in the alternative pathway are notated in capitals (IF, B, D and 
P). The antigen-antibody complex that initiates the classical 
pathway is denoted as SA, while the activating substance for the 
alternative pathway is represented by S. The control proteins of 
the complement sequence are generally abbreviated as Cl.INH 
(CI esterase inhibitor); C3b.INA (C3b inactivator); ßlH; and AI 
(anaphylatoxin inactivator). 
2.3. IMTIUNOCHEMISTRY OF COMPLEMENT 
2.3.1. The classical activation unit (fig. 2) 
Activation of the factors of this unit leads to the formation 
of a C3 convertase. The activation is initiated by binding of the 
CI molecule to antigen-antibody complexes, or to non-specifically 
aggregated immunoglobulins (IgG and IgM). CI consists of 3 sub-
units Clq, Clr, and Cls presumably in equimolar ratio in the 
presence of one molecule Ca which is necessary for the struc-
tural integrity of the CI molecule (Lepow et al, 1963) . Recently 
a fourth subunit of CI has been described, called Clt (Assimeh 
and Painter, 1975). This subunit is not necessary for the hemo-
lytic activity of CI, and its precise function is as yet unknown. 
The process is started by binding of Clq to the immunoglobulin. 
The binding site for Clq resides in the IgG molecule in the 
second constant domain (CH2) of the Fc region (Ellerson et al, 
1972) , and in the fourth constant domain (CH4) of the IgM mole-
cule (Hurst et al, 1975). For the activation of Clq at least 
2 IgG antibodies are necessary, which moreover should be located 
in a certain spatial relationship, while in the case of IgM one 
molecule is sufficient (Borsos and Rapp, 1965). The Clq subunit 
consists of 6 identical non-covalently linked subunits, with an 
N-terminal collagen-like region and a C-terminal globular segment 
(Reíd and Porter, 1976). The six subunits are joined at their 
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SA 
^-Clqrs 
SA C i 
= = inhibition by Cî INH 
• S.CÎbiô classical Сз 
convertase 
C4c-C4d 
Figure 2. The classical activation unit 
N-terminal regions to form a stem fibril from which branch the 
individual C-globular segments (fig. 3). Each of these six glo­
bular portions can bind to one IgGl, IgG2, IgG3 or IgM antibody. 
Binding of at least two globular portions of the Clq molecule 
leads to steric changes in the Clr subunit (Reid and Porter, 
1976), which results in the formation of cTr, that has an esterase 
activity (Naff and Ratnoff, 1968). The natural substrate of cTr 
is the Cls subunit, that obtains esterase activity after cleavage. 
cTs and cTr are susceptible to the naturally occurring cT in­
hibitor (CT.INH) (Pensky et al, 1961). cT.INH stoichiometrically 
inhibits the enzymatic function of cTr and cTs (Gigli et al, 1968) . 
Only if Clr is formed in such amounts that it locally exceeds the 
inhibitory capacity of cT.INH, the next activation step follows. 
The substrates of CTs are the complement factors C4 and C2. C4 is 
cleaved into two fragments by Cls, a larger fragment C4b which 
binds to cell membranes and immune complexes, (Müller-Eberhard 
and Biro, 1963) and a smaller fragment C4a that is released into 
the fluid-phase. This latter fragment has weak smooth muscle 
contractile properties (Schreiber and Müller-Eberhard, 1974). 
Bound C4b has also an affinity to immune adherence receptors, 
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present on various cells, to which C3b is preferentially bound 
(Cooper, 1969). The binding of C4b to the cell membrane is very 
labile; most molecules dissociate and are released into the 
fluid phase, where they are rapidly cleaved by C4b-inactivator 
into C4c and C4d. This leads to loss of both hemolytic 
activity and the capacity to bind to immune complexes or cell 
antibody binding site 
globular portion (C terminal) 
end fibril j „„(аде,,.,.!« 
J portion 
stem fibril Μ N terminal) 
Figure 3. Ultrastructural composition of human Clq (after Reid 
and Porter, 1976) — , portions of the moleoule pointing 
towards the reader; , portions of the moleoule 
pointing away from the reader. 
membranes. This C4b inactivator is very probably identical with 
C3b.INA (Cooper, 1975). The next step after cleavage of C4 is 
the splitting of C2 by cTs in C2a and one or more minor fragments 
(Polley and Müller-Eberhard, 1968). Before C2 is cleaved, it is 
loosely bound to the C4b molecule, which requires the presence 
of Mg (Sitomer et al, 1966). The presence of C4b on the cTs 
molecule enhances the splitting of C2 by Cls, by an allosteric 
modification of cTs or C2 (Gigli and Austen, 1969). The C2a 
molecule forms on the cell membrane a bimolecular complex with 
C4b, yielding the classical C3 convertase C4b2a, which cleaves 
and activates C3 (Müller-Eberhard et al, 1967) . For this C3 
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Splitting activity Cis is not required. Within the C4b2a complex 
C4b is responsible for the binding to the target cell membrane 
(Müller-Eberhard et al, 1967) while the enzymatic properties 
reside in the C2a fragment. After cleavage of C3 and assembly of 
C3b into the complex, forming the classical C5 convertase C4b2a3b, 
C2a also carries out the enzymatic cleavage of C5 (Cooper, 1971; 
Shin et al, 1971). Once formed C3 convertase has a relatively 
short half-life (5 min. at 37 C), because C2a easily dissociates 
into the fluid phase, where it is readily inactivated into C2i. 
The C2i molecule is not re-usable for formation of a C4b2a com-
plex in contrast to C14b that again can react with a native C2 
molecule to restore C4b2a. 
2.3.2. The alternative activation unit (fig. 4) 
Activation of the alternative pathway also yields C3 conver-
tase activity, but without the use of the classical activation 
factors CI, C4 and C2. Activation of the alternative pathway can 
be initiated by IgA immunoglobulins, polysaccharides (zymosan, 
inulin, endotoxins of gram negative bacteria), dextran sulphate, 
T-cell independent antigens, B-cell mitogens (pokeweed), and other 
substances (Götze and Müller-Eberhard, 1977). No specific chemi-
cal structure responsible for this activation has hitherto been 
recognized. However, all activating substances have a polymeric 
structure, consist of repeating subunits and contain poly-
saccharides. On the surface of the activating substance, a very 
labile C3 convertase is formed which is an Mg dependent complex 
of the initiating factor (IF), factor B, factor D, and native C3. 
The existence of the IF has been discovered after recognition of 
a certain protein present in sera of some patients with hypo-
complementaemia and membranoproliferative glomerulonephritis 
(Spitzer et al, 1969) or partial lipodystrophy (Sissons et al, 
1976). This protein, called C3 nephritic factor (C3MeF), generates, 
in the presence of factor B, factor D, C3, and tig , a stable 
soluble C3 convertase (Schreiber et al, 1975). Antisera prepared 
against C3NeF, remove a factor from normal serum, after which 
activation of the alternative pathway with for instance zymosan 
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52-СЭЬРВЬ 
Ρ stabilized Сэ 
convertase 
C 3 № F stabilized 
Сз convertase 
C3b dependent Сз 
convertose (labile) 
C5 convertase 
(labile) 
Ρ stabilized CS 
convertase 
Figure 4. Activation sequence of the alternative pathway 
(Modified, after Götze and Müller-Eberhard, 1977), 
сап no longer be induced (Schreiber et al, 1976a). The factor 
removed by anti C3NeF antisera was called initiating factor (IF). 
However, this IF is a distinct protein, not identical with C3NeF. 
The nature of interactions between the activating substances and 
IF are completely unknown. However, the initiation is started 
by the formation of an initial C3-convertase. After formation of 
this convertase on the surface of the activating substance, the 
enzyme deposits formed C3b in its vicinity. The formation of C3b 
is a prerequisite for the further activation of the alternative 
pathway. Soluble or bound C3b has an affinity to factor B, with 
which it forms, in the presence of Mg , a bimolecular complex 
(Medicus et al, 1976a). This complexed factor В becomes susceptible 
to factor D (Vogt et al, 1976) which cleaves factor В in two 
fragments Bb (retained in the complex) and Ba (dissociated into 
the fluid phase). Complex СЗЬВЬ is the alternative pathway C3 
convertase (Müller-Eberhard and Götze, 1972). The formation of 
this alternative C3 convertase is further enhanced by C3b (the 
so-called amplification loop). The СЗЬВЬ enzyme has when present 
in the fluid phase only C3 splitting properties (Medicus et al, 
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1976b) but in the solid phase it also has a slight C5 splitting 
activity (Medicus et al, 1976a), which is greatly enhanced when 
more than one molecule C3b is present in the СЗЬВЬ complex 
(S2-C3b(n)Bb) (Medicus et al, 1976c). This is quite similar to the 
classical pathway where the C3 convertase (C4b2a) obtains C5 
splitting activity after incorporation of a C3b molecule (C4b2a3b). 
Both C3b(n)Bb and СЗЬВЬ have properdin (P) activating activity. 
After binding,? undergoes conformational changes by which acti­
vated properdin (P) is formed (Götze et al, 1976). The presence 
of Ρ stabilizes the C3b(n)Bb complex and prolongs its half-life 
by inhibiting the spontaneous dissociation of Bb from the complex 
(Fearon and Austen, 1975; Medicus et al, 1976c). Furthermore Ρ 
indirectly makes the СЗЬВЬ complex less susceptible to C3b in-
activator (C3b.INA) because C3b.INA cannot cleave C3b into C3c 
and C3d as long as C3b is complexed with Bb (Fearon et al, 1976). 
In contrast to earlier ideas properdin itself does not play a 
central role in the alternative pathway. It is activated rather 
late in the sequence, and its sole function seems to be to 
stabilize the С3b(n)Bb complex. 
As can be seen in figure 4 there exists also another molecular 
sequence in the alternative pathway. After formation of S2-C3b 
activated fluid phase properdin (P) can bind to the C3b molecule. 
In the presence of factor В and D this enzyme obtains C3 splitting 
activity which subsequently leads to the formation of a Ρ stabi­
lized C5 convertase. (Götze and Müller-Eberhard, 1974). The formed 
СЗЬР is susceptible to C3b.INA which splits the complex in S2-
C3d and СЗсР. The latter complex can dissociate with recovery of 
P. However, this sequence seems to be less important and there are 
even serious doubts whether it exists under physiological condi­
tions (Götze and Müller-Eberhard, 1977). 
As already mentioned sera of some patients with membrano-
proliferative glomerulonephritis contain a protein called C3NeF. 
The presence of C3NeF is accompanied by depressed serum concen-
trations of C3, B, and P, but relatively normal concentrations CI, 
C4 and C2 (Gewürz et al, 1968; McLean and Michael, 1973) . This 
proves that only activation of the alternative pathway has taken 
place. If C3NeF containing serum is added to normal serum C3 
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activation will occur. C3NeF has tvo functions, first it induces 
the formation of a C3 convertase (Schreiber et al, 1975), second 
it stabilizes the C3 convertase so that it becoires insusceptible 
to the control proteins of the alternative pathway C3b.INA and 
B1H globulin (Daha et al, 1976). 
Recently it has been reported that C3NeF is an antibody pro­
bably directed against alternative C3 convertase СЗЬВЬ (Davis et 
al, 1977). However, this report is in contrast with the ideas of 
the group of Müller-Eberhard, who think that C3NeF represents a 
permanently active form of IF (Schreiber et al, 1976a, 1976b). 
Further elucidation of the structure, function and reaction pro-
ducts of IF is necessary for a better delineation of the role of 
C3Ner m disease, (see addendum: page 45). 
Finally e few remarks should be made regarding the control 
systems in the alternative pathway. An important control mechanism 
is the lability of the formed enzymes. By their rapid decay a 
prolonged and sustained action is prevented. The intrinsic decay 
of the СЗЬВЬ complex is the result of the rapid dissociation of 
Bb out of the complex. There also exists an extrinsic decay due 
to C3b.INA and B1H (fig. 5). C3b.INA was first recognized by 
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Tamura and Nelson (1967), who found that it blocked C3b in immune 
adherence and hemolysis. Later on it was found that СЗЬ.ІЫА 
cleaved C3b into two fragments C3c and C3d (Ruddy and Austen, 
1971). The action of СЗЬ.ІМЛ leads to four effects: destruction 
of the C5 convertase activity of C4b2a3b, inhibition of binding 
of factor В to C3b, inhibition of immune adherence, and of phago­
cytosis. It is the major control protein of the amplification 
loop, which can be derived from the observation that a patient 
with a genetic deficiency of C3b.lNA had very low levels of C3 
and factor В (Alper et al, 1972a). As already mentioned C3b 
cannot be cleaved by СЗЬ.ІМА if it is complexed with Bb. The in­
trinsic decay of СЗЬВЬ is inhibited by P. The stabilizing effect 
of Ρ is antagonized by the second control protein BiH (Weiler et 
al, 1976), whereafter Bb can dissociate again out of СЗЬВЬ. 
Subsequently C3b can be cleaved by C3b.INA (fig. 5). If the com­
plex is stabilized by C3NeF it is much more (approximately 200 
fold) resistant to BiH and thus escapes from the control mecha­
nisms. This results in sustained C3 cleavage (Daha et al, 1976). 
2.3.3. The terminal attack unit (fig. 6) 
This phase of the complement sequence is less well understood 
than the preceding steps. After formation of the classical or al­
ternative C3 convertase, C3 is cleaved into a major fragment C3b 
which can be incorporated into the C3 convertase, and a minor 
fragment C3a which evokes important immunobiological effects that 
will be discussed in the following section. After incorporation 
of C3b into the C3 convertase the specificity of the enzyme is 
changed, such that it now has C5 splitting activity (Shin et al, 
1971; Daha et al, 1976). C5 is cleaved into a major fragment C5b 
which interacts physicochemically with C6 and C7 and a minor 
fragment C5a that has a variety of immunobiological properties 
that will be discussed later. The binding of C6 to C5b must occur 
immediately after the generation of C5b, otherwise C5b will decay 
into cytolytically inactive C5i (Nilsson and Müller-Eberhard, 
1967a). Binding of C6 and later on also C7 can occur both on the 
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membrane and in the fluid phase. The formation of the trinolecular 
complex C5b67 is non-enzymatic, v/hich implies that no cleavage 
occurs and that its formation is the result of non-covalent assem­
bly. The C5b67 complex binds to membranes via its C5b part. If the 
fluid phase C5b67 does not encounter a membrane, the binding site 
decays and cytolytically inactive С5І67 is formed. The fluid phase 
C5b67 complex can also bind via C5b to membranes not sensitized 
with antibody, thereby extending the cytolytic effects of comple­
ment to "innocent bystander" cells. This mechanism is known as 
"reactive lysis" (Thompson and Lachmann, 1970). After formation 
of the trimolecular complex C5b67 one molecule C8 becomes attached 
whereafter six C9 molecules can bind to C8 to form a decamolecular 
complex (Kolb and Müller-Eberhard, 1973). This complex causes 
cytolysis by an impairment of osmotic regulation of the cell. 
2.4. IMMUNOBIOLOGY OF COMPLEMENT 
The biological activities that are generated during the comple-
ment cascade are mainly a consequence of activation of C3 and the 
terminal attack sequence. These activities can be divided into 
three types : 
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1. alteration of the target complex (e.g. immune adherence, cyto-
lysis) 
2. alteration of the nicro-environment (anaphylaxis, leucotaxis) 
3. systemic effects (interaction with coagulation system etc.). 
2.4.1. Alteration of the target complex 
Immune adherence 
One of the most important biological activities generated 
during complement activation is the immune adherence phenomenon. 
Immune adherence is the binding of C3b coated immune complexes, 
cells, or particles to cells bearing a C3b receptor on their sur­
face. Such C3b receptors are present on human polymorphonuclear 
leukocytes, macrophages, erythrocytes, В lymphocytes, monocytes 
and renal glomerular basement membrane. Presumably an intact C3b 
molecule is required, because it was shown that the phenomenon 
is inhibited by C3b.INA. (Tamura and Nelson, 1967; Gigli and 
Nelson, 1968). Bound C4b shows also an affinity to the same re­
ceptors (Cooper, 1969). Binding to the membrane receptor acts as 
a signal to start certain cellular processes, and the resulting 
biological effects depend on the cell type involved. Immune ad­
herence to phagocytic cells results in an enhancement of phago­
cytosis (Gigli and Nelson, 1968). The biological importance of 
this event can be derived from the observation that in patients 
who are genetically deficient in C3 repeated and severe bacterial 
infections can occur (Alper and Hosen, 1974). If immune adherence 
with non-phagocytosable particles takes place extracellular 
release of lysozymes occurs, which can contribute to inflammatory 
damage (glomerulonephritis, graft-rejection) (Henson, 1972). 
Immune adherence to В lymphocytes seems to be important for antibody 
production, because C3 depletion leads to a delayed antibody pro­
duction towards thyrrus-dependent antigens but not to thymus-
independent antigens (Pepys, 1974). It seems therefore very likely 
that C3 and C3 receptors play a role in the T-B cell cooperation. 
There exists also evidence indicating that C3 plays a role in 
В cell proliferation. It has been even suggested that the Τ cell 
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independency of certain antigens is caused by the fact that they 
can initiate the alternative pathway leading to the formation of 
C3b on the surface of these antigens. This can result in trigger­
ing of the В cell without Τ cell help (Dukor et al, 1974) . How­
ever the fact that in a patient with a genetic deficiency of C3 
a normal response to antigens was found, strongly suggests that 
C3 is not an absolute requirement for antibody production (Alper 
et al, 1972b). Immune adherence to macrophages activates the 
macrophage and induces the release of several lysosomal enzymes, 
like hydrolases and proteinases. One of these enzymes has C3 
splitting activity (Schorlemmer and Allison, 1976) . Since macro­
phages synthesize factor C3 (Lai A Fat and van Fürth, 1975) and 
factor В (Bentley et al, 1976), and activated macrophages even 
release C3b (Allison, 1978), СЗЬВЬ convertase can be formed in 
the vicinity of the macrophage. This convertase enhances further 
C3b generation which can lead to subsequent activation of other 
macrophages, so that serial activation can take place. These in 
vitro findings have probably immunopathological significance in 
the production of chronic inflammatory responses evoked by bac­
terial or fungal cell walls, or other polyanions. They can induce 
prolonged macrophage activation, by generation of C3b via the 
alternative pathway (Schorlemmer et al, 1977). Furthermore C3b 
activated macrophages produce C3a (Ferluga et al, 1978) which has 
cytolytic properties against tumor cells (Ferluga et al, 1976). 
Immune adherence of C3b to human monocytes gives a marked increase 
in the generation of tissue thromboplastin by the monocyte 
(Prydz et al, 1977). C3b receptors have not been found on human 
platelets, but in experimental animal studies immune adherence 
to platelets can lead to secretion of coagulation active and vaso­
active intracellular products (Henson and Cochrane, 1971) and to 
aggregation of platelets. 
Cytolysis 
Generation of the membrane attack unit with formation of the 
multimolecular C5-C9 complex on the membrane induces cytolysis 
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of cells and gram negative bacteria. Kinetic studies revealed 
that cytolysis is a one hit phenomenon, or in other words that 
one C5-C9 complex on a membrane is sufficient for cytolysis 
(Kitamura et al, 1976). This makes it very unlikely that cyto-
lysis is caused by enzymatic attack, because this process is a 
multi-hit process. Work by the group of Mayer (Mayer, 1972; 1977; 
Hammer et al, 1975; 1977) indicates that the lesion produced is 
a transmembrane channe], which is formed by a hydrophobic outer 
ring and an hydrophilic inner core. During the formation of the 
C5-C9 complex conformational changes of the C8 and C9 molecule 
lead to the exposure of hydrophobic polypeptide regions from the 
interior of the molecule. If this occurs in the immediate vici-
nity of the lipid bilayer of the membrane, insertion of the mole-
cule will occur with formation of the transmembrane channel. 
Through this transmembrane channel salt and water will flow into 
the cell because of the Donnan effect. This causes swelling which 
leads to bursting of the cell membrane and release of macro-
molecules . 
Virus-neutralisation 
Under certain conditions antisera against viruses have little 
or no ability to neutralize viruses, unless CI, C4, C2 and C3 are 
present, presumably to cover the surface of the virus (Daniels 
et al, 1970) . 
Solubilization of immune complexes 
Immune complexes can interact with the complement system at 
several levels. Clq has 6 binding sites for immunoglobulins, while 
C4b and C3b can bind to immune complexes. 
Recently, Miller and Nussenzweig (1975) described a new function 
of the complement system that consists of solubilization of pre-
cipitated Ag-Ab complexes. This solubilization is dependent on 
C3, which is the effector molecule in this release reaction 
(Takahashi et al, 1977). The complex release activity (CRA) is 
generated via the alternative pathway, and this can occur in the 
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absence of the classical activation unit (Miller and Nussenzweig, 
1975). However, the presence of C2, C4 and Ca leads to a more 
efficient release (Czop and Nussenzweig, 1976) . The late compo-
nents (C5-C9) play no role in CRA since it was found unaltered 
with C5 or C6 deficient sera. The reaction leading to CRA is 
probably started by binding of Clq to the Ag-Ab complex, and sub-
sequently some C3b molecules are deposited on the immune complexes 
via the classical C3 convertase. Via the amplification loop C3b 
dependent alternative C3 convertase is formed on the immune com-
plexes which greatly enhances further deposition of C3b. The C3b 
molecules somehow interact with the complexes and lead to dis-
ruption of the lattice formation. After dissociation of antigen 
from antibody the C3 molecules prevent reassociation and cross-
linking with antigen (Takahashi et al, 1976). Although this re-
lease activity was studied in vitro, it has probably relevance 
in vivo, where by this mechanism complement can prevent deposi-
tion of immune complexes in tissues. It could explain the finding 
that in patients with a congenital deficiency of the complement 
system, immune complex mediated diseases are frequently found 
(see 2.5.1.) . 
2.4.2. Alteration of the micro-environment 
Alterations of the micro-environment may be brought about 
primarily by complement-mediators formed during complement acti-
vation and released in the fluid phase (C3a, C5a). They increase 
vascular permeability, contract smooth muscle and attract phago-
cytic cells. Alternatively, alterations are induced by secondary 
mechanisms, such as release of lysozymes from neutrophils after 
immune-adherence with non-phagocytosable particles or surfaces, 
or exposure of platelets to vascular basement membrane after 
complement mediated damage of endothelial cells. Both primary and 
secondary mediators are important in inflammatory processes 
associated with immune reactions. 
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Permeability factors 
The most important factors that lead to an increased vascular 
permeability, generated during complement activation are the split 
products of C3 and C5: C3a and C5a. These effects are mediated by 
histamine liberated from mast-cells and basophils. Moreover, these 
factors have smooth-muscle contractile activity, which is inde-
pendent of histamine release (Vallota and Müller-Eberhard, 1973). 
The effects of C3a and C5a on smooth muscle and vascular permea-
bility promote sludging and margination of leukocytes, thereby 
producing optimal conditions for Chemotaxis, which is an addition-
al activity of C3a and C5a. The vasoactive properties of C3a and 
C5a are susceptible to rapid enzymatic inactivation by anaphyla-
toxin inactivator (A.I.) which cleaves arginine (СЗа), or arginine 
or lysine (C5a) from the molecule (Bökisch and Müller-Eberhard, 
1970) . 
As already mentioned, it has been shown in animal experimental 
studies that vasoactive peptides can be released by thrombocytes 
after binding of C3b to their C3b receptor. 
In sera from patients with heriditary angioneurotic edema 
(HANE), which is caused by an autosomal dominant deficiency of 
Cl.INH, a complement factor is found which is called "C-kinin". 
This protein has vasoactive properties, and is responsible for the 
clinical manifestations in HANE patients (Donaldson et al, 1969). 
During an attack pathologically increased CI activity can be found 
in sera from these patients, accompanied by very low levels of 
C4 and C2. (Lepow, 1971). The high cT activity is due to the lack 
of its inhibitor Cl.INH, which leads to an increased cleavage of 
the substrates of cT i.e. C4 and C2. Intradermal injection of cT 
causes a local increase in vascular permeability in normal indi-
viduals, an extensive area of angioedema in HANE patients, while 
no reaction is seen in C2 deficient patients (Klemperer et al, 
1968) . A peptide having the same vasoactive properties has been 
isolated from incubation mixtures of CI, C4 and C2. It is very 
likely that the polypeptide, (called "C-kinin") responsible for 
the clinical features of HANE-patients, is liberated from C2 by 
the action of cTs in the presence of C4. 
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Chemotaatia factors 
Three products generated during the complement sequence attract 
leucocytes by their chemotactic properties: C3a, C5a and probably 
fluid phase C5b67 (Ward et al, 1965; Ward, 1972). The most potent 
among these three is C5a, C3a has a much lower activity. Although 
chemotactic activity of C5b67 has been described in in vitro ex­
periments, serious doubts exist whether this effect is of signi­
ficance in vivo. Thus, C6 or C7 deficient sera have unimpaired 
chemotactic properties (Snijderman et al, 1969; Stecher and Sorkin, 
1969; Hannema et al, 1975; Lim et al, 1976). The chemotactic 
factors C3a and C5a are not only formed during complement acti­
vation but are also liberated through the action of plasmin, tryp­
sin and tissue- and neutrophil proteinases (Ward, 1972). Chemo­
tactic factors do not only attract neutrophils but also eosino­
phils and monocytes. After exposure to chemotactic molecules, 
the cell becomes unresponsive to further attraction. This keeps 
the cell at the inflammatory focus, so that other cell functions 
can come to expression. One of the properties of neutrophils is 
to release a proteinase that can form C5a, so that vascular 
permeability will increase even more and further accumulation of 
leucocytes and monocytes will occur (Snijderman et al, 1971a). 
The chemotactic properties are abolished by a serum factor called 
chemotactic-factor inactivator. This inactivator is distinct 
from anaphylatoxin inactivator, that abolishes the vasoactive 
activities of C3a and C5a (Till and Ward, 1975) . 
2.4.3. Systemic effects of complement 
МоЪгЪъгаЬгоп of leucocytes 
During cleavage of C3 a factor is formed (called leucocyte 
mobilizing factor) which mobilates leucocytes from the bone-
marrow reserves into the circulation (Rother, 1972). The relevance 
of this factor in vivo can be derived from the fact that in pa­
tients with a genetic deficiency of C3, leucocytosis does not 
occur during bacterial infections (Alper and Rosen, 1974). 
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Inter-relations between the complement-, the alotting-3 the кгпгп 
generating-, and the fibrinolytic system 
Activation of the clotting system can directly lead to comple­
ment activation. The mechanisms involved will be discussed in this 
section. Although direct activation in the onposite direction does 
not exist, certain effects produced by complement activation 
(release of platelet factors due to immune adherence, lysis of 
platelets, release of coagulatory enzymes from leucocytes, etc.) 
can secondarily induce activation of the coagulation sequence. 
A central place in the relation between these enzymatic cascades 
is the Hageman factor (F XII), as can be seen in figure 7. 
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Figure 7. Inter-relations between the clotting-, kinin generating-, 
fibrinolytic-, and complement system. 
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Activation of Hageman factor leads to four different functions 
(Kaplan and Austen, 1975): 
a) Initiation of the intrinsic pathway of coagulation, by acti-
vating factor XI, which induces further activation of the 
clotting sequence. 
b) Initiation of fibrinolysis by formation of plasmin, the fibri-
nolytic enzyme. Activated factor XII activates plasminogen-
proactivator to plasminogen activator which converts plasmino-
gen to plasmin. Plasmin cleaves fibrin and fibrinogen into 
smaller fragments. 
c) Activation of the kinin-system, by liberation of kallikrein 
from prekallikrein. The formed kallikrein cleaves kinins from 
kininogen. The formation of kallikrein by activated factor XII 
is enhanced by plasmin, which splits Xlla into smaller frag-
ments (Xll-f), that have a much greater capacity than Xlla to 
form kallikrein out of prekallikrein. Furthermore plasmin can 
directly, without F XII, convert prekallikrein to kallikrein. 
d) Activation of the complement system. Activated Hageman factor 
can also via plasmin, trigger the complement sequence at two 
different levels. First plasmin has the capacity of cleaving 
CI into its active form cT; second it can split C3 in the fluid 
phase into its biologically active fragments C3a and C3b. 
The membrane attack unit is not activated by Hageman-factor. 
Activation of Hageman factor can occur by contact with bio-
logical materials presenting dense negative charges. These inter-
act with positively charged aminoacids in the molecule (e.g. 
arginine) leading to a rearrangement into the molecule, with 
uncovering of the enzymatic site. Collagen, vascular basement 
membrane, uric acid, pyrophosphate and a number of insoluble 
materials (glass, kaolin, etc.) belong to these activating sub-
stances. It has been found that antigen-antibody complexes and 
immune aggregates can activate F XII after binding of Clq (which 
exhibits a chemical composition similar to that of collagen) 
(Austen, 1974). Furthermore, complement-mediated immunologic tissue 
injury is very often primarily localized at the surface of blood 
vessels. The alterations of the vascular basement membrane induced 
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by this injury can result in activation of Hagenan factor. There 
is however as yet no experimental evidence that immune complexes 
are able to activate F XII directly. 
At several levels inhibition by Cl.INH can occur (see fig. 7), 
so that all effects of activated factor XII can become blocked. 
Deficiency of Cl.INH, as in patients with heriditary angioneurotic 
edema, leads to unappropriate activation of factor XII, resulting 
in kinin generation and complement activation, which are res-
ponsible for the clinical symptoms. 
Activation of factor XII leads to a number of biological 
activities. Plasminogen activator and kallikrein both have chemo-
tactic properties (Kaplan et al, 1972; 1973), cleavage products 
of fibrinogen and fibrin have also chemotactic properties, and 
can enhance vascular permeability (Marder, 1971; Barnhart et al, 
1971), while the formed kinins are potent vasoactive peptides. 
So far we have presented some data about the influence of the 
coagulation system on complement. There exists very little evi-
dence that there are also direct interactions in the opposite 
direction. Deficiencies of virtually all classical complement 
pathway factors have been reported in man, but defects in coa-
gulation were not mentioned in these reports (Brown, 1975). 
However, in rabbits congenital deficient in C6 (Zimmerman et al, 
1971), and in guinea pigs deficient in C4 (Dodds et al, 1977) a 
decrease in coagulation activity was found that normalized after 
reconstitution of the deficient factor. The fact that coagulation 
is normal in humans with C6 deficiency (Heusinkveld et al, 1974) , 
while C6 deficient rabbits have a clotting defect is probably 
the result of a peculiar property of the rabbit platelet, in that 
it requires all complement factors for the release of initiating 
clotting factors (Rosen, 1975), and for aggregation (Fong and 
Good, 1975). As already mentioned earlier, in many experimental 
animals (including the mouse), but not in man, an indirect rela-
tion exists between complement and the coagulation system via the 
platelets, because of their C3b receptors. Binding of C3b to these 
receptors leads to platelet aggregation with subsequent release 
of platelet procoagulants (Henson and Cochrane, 1971). If the 
complement cascade is further activated up to C9 on the surface 
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of the platelet, platelet lysis does even occur. This is accom-
panied by a substantial increase in the release of platelet 
factors (Henson, 1970) . However, even this link between comple-
ment and coagulation is incomplete, because it does not lead to 
a direct triggering of the coagulation system. It only can 
accelerate an already initiated clotting sequence. Probably the 
most important interaction between complement and coagulation 
takes place on the endothelium of small vessels via a number of 
biological activities generated during complement activation. 
Generation of C3a and C5a causes increased vascular permeability 
by releasing vasoactive amines from basophils and mast cells, 
and by inducing release of serotonin from platelets via platelet 
aggregation factor liberated fron basophils (Benveniste, 1974). 
Neutrophils and monocytes marginate at the sites of altered vas-
cular permeability, leading to endothelial cell damage (Stewart 
et al, 1974), release of lysosomal enzymes (Janoff, 1970), and 
release of a leucocyte procoagulant which can initiate coagula-
tion (Kociba et al, 1972; Prydz et al, 1977). Local coagulation 
is further enhanced by platelet aggregation on exposed subendo-
thelial surfaces (Baumgartner, 1974), and by Hageman factor 
activation by the altered vascular basement membrane. 
2.5. GENETICS OF THE COMPLEMENT SYSTEM 
2.5.1. Complement deficiency in man 
Genetic defects have now been described for almost all the 
complement components in man (see table II). In most cases the 
defects are transmitted as autosomal recessive traits. Some of 
these deficiencies predispose to certain diseases, which are 
listed in table II. As mentioned previously deficiency of Cl.INH 
is associated with heriditary angioneurotic edema. (Donaldson and 
Evans, 1963). The disease consists of recurrent attacks of non-
inflammatory swelling localized in the subcutaneous tissues, 
intestinal wall, airways and lungs. Laryngeal edema may often be 
fatal (Donaldson and Rosen, 1966) . The deficiency is most pro-
bably transmitted as an autosomal dominant trait. Attacks are 
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TABLE il. Deficienaies of the complement system in man* 
Deficient factor Clinical findings 
Clq 
Clr 
Cls 
C4 
C2 
C3 
C5 
C5 dysfunction 
C6 
C7 
С 
combined immunodeficiency state 
SLE, glomerulonephritis, reumatoid disease 
SLE 
SLE 
none, discoid LE, SLE, anaphylactoid purpura, derraa-
tomyositis, glomerulonephritis 
infections 
SLE 
Leiner's syndrome (eczema and secondary infections) 
none, infections 
none, Raynaud 
gonococcal infection, SLE 
Deficient control protein 
Cl.INH 
С3b.IMA 
heriditary angioneurotic edema, SLE 
infections 
* Based on Day and Good, 1976; Alper and Rosen, 1976, Agnello, 1978 
evoked by an unappropriate activation of Cl, possibly via plasmin 
generated after activation of Hageman factor. One patient has 
been described with a deficiency of another control protein, 
C3b.INA (Alper et al, 1972a). In the serum of this patient very 
low C3 levels have been found. Clinically the deficiency is accom-
panied by a life long history of severe infections. 
2.5.2. Complement deficiency in animals 
In animals also a number of complement deficiencies (C4, C5 
and C6) have been found. Because we made use of these animals in 
our experiments (see chapter 5 and 7) the immunobiological effects 
that are found in association with these complement deficiencies 
will be described here in more detail. 
C4 deficienoy in guinea pigs 
In 1970 Ellman et al described a strain of guinea pigs that 
lacked C4. This deficiency is transmitted as an autosomal reces-
sive trait (Ellman et al, 1970). The serum of these animals lacks 
hemolytic complement activity, which can be restored by the 
addition of normal guinea pig serum or of purified guinea pig C4. 
Serum concentrations of the other complement components in C4-
deficient guinea pigs are normal except for C2 (50 percent of 
normal value). The alternative pathway of complement is entirely 
normal (Frank et al, 1971). A number of immunological mechanisms 
have been studied in these animals (Ellman et al, 1971). Passive 
cutaneous anaphylaxis, contact and delayed hypersensitivity, and 
the cellular exsudative response to foreign body were normal. 
Somewhat striking was the finding that the direct and reverse 
passive Arthus reaction are unimpaired, while in C6 deficiency 
(Biro, 1966) and in experimental C3 depletion (Cochrane et al, 
1970) these reactions are diminished. This difference is the 
result of the fact that guinea pig antibodies are able to acti-
vate the alternative pathway, so that via this bypass mechanism 
the late acting complement components can become activated (Sand-
berg and Osier, 1971). C4 deficient guinea pigs show furthermore 
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a decrease in the clearance of autologous erythrocytes coated 
with antibodies. Again this can be restored by the addition of 
normal guinea pig serum. Clearance of bacteria v/hich is dependent 
of alternative pathway activation is normal in C4 deficient guinea 
pigs. Induction of Chemotaxis in C4 deficient guinea pigs is 
normal, but the kinetics of the production of chemotactic factors 
shows a latency period which is characteristic for alternative 
pathway activation (Clarck et al, 1973). 
CS deficiency in mice 
Genetically defined complement deficiency in mice was found in 
many inbred mouse strains. The locus coding for the presence or 
absence of a β globulin was originally designated He' (Erickson 
et al, 1964) or MuBl (Cinader et al, 1964) . Later on it was found 
that the product of this locus was C5 (Nilsson and Müller-Eberhard, 
1967b). This deficiency is transmitted as an autosomal recessive 
trait. The serum of these mice completely lacks hemolytic comple-
ment activity. In general C5 deficient mice are as healthy as 
normal mice, although there are some immunobiological deficiencies. 
C5 deficient mice are more susceptible to infections with Coryne-
bacterium Kutscher! (Caren and Rosenberg, 1966). The clearance of 
erythrocytes coated with antibodies and bacteria (S. typhimurium 
and E.coli) was equal to normal mice (Stiffel et al, 1964) . 
The finding that Chemotaxis for leucocytes was not produced by 
C5 deficient serum after incubation with immune complexes or 
zymosan, has lead to the identification of the central function 
of C5a in Chemotaxis (Ward et al, 1965). This defect was also 
found to exist in vivo. Injection of endotoxin into the peritoneal 
cavity of C5 normal mice resulted in the generation of a factor 
that was chemotactic for mouse polymorphonuclear leucocytes and 
was followed by the accumulation of these cells in the peritoneal 
fluid. By contrast the same procedure carried out in C5 deficient 
mice did not reveal chemotactic activity tested in vitro nor 
accumulation of polymorphonuclear leucocytes (Snijderman et al, 
1971b). There exist two brief reports in the literature concerning 
the Arthus phenomenon in C5 deficient mice, and it was found to 
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be unimpaired in comparison to normal mice (Linscott and Cochrane, 
1964; Crisler and Frank, 1965). With immunofluorescence studies 
C3 was found in Arthus lesions in C5 deficient mice (Linscott and 
Cochrane, 1964). From these findings it might be concluded that 
activation up till C3 is sufficient to induce the Arthusphenomenon, 
however in C6 deficient rabbits an impaired Arthus reaction has 
been found. Since nephrotoxic serum nephritis (Lindberg and Rosen­
berg, 1968; Unanue et al, 1967) and autoimmune disease occur in 
C5 deficient mice (Howie and Helyer, 1965) it is likely that these 
immunologic inflammatory reactions can occur without activation 
of the terminal complement attack sequence. Cellular immune res­
ponses are normal in C5 deficient mice since normal delayed hyper­
sensitivity reactions and skin allograft rejection have been ob­
served (Caren and Rosenberg, 1965; Crisler and Frank, 1965) . 
Св deficiency in rabbits 
In 1961 Rother discovered an inborn defect in the complement 
system in certain rabbits, which turned out later to be caused by 
a deficiency of C6 (Rother and Rother, 1961; Rother et al, 1966a). 
The characteristic is inherited as a single autosomal recessive 
trait. The serum of these animals lacks hemolytic complement and 
bactericidal activity which are both restored after addition of 
C6 (Rubin et al, 1967; Rother et al, 1964a). Passive Arthus 
reaction in C6 deficient rabbits was macroscopically absent or 
incomplete (Rother et al, 1964b). However, on histologic examina­
tion, it was found that the leucocyte infiltration was only slight­
ly less than in normal rabbits. The most striking difference was 
the complete absence of hemorrhagic necrosis (Biro, 1966), that 
is considered to be a hallmark of the Arthus reaction. As already 
mentioned these observations are in apparent contrast to those of 
unimpaired Arthus reactions in C5 deficient mice (Linscott and 
Cochrane, 1964; Crisler and Frank, 1965). However, these latter 
studies only mention leucocyte infiltration and fail to give in­
formation on the presence of hemorrhagic necrosis. If one assumes 
that necrosis was also absent in the C5 deficient mice, the fin­
dings can be explained by the hypothesis that, for leucocyte 
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accumulations, activation up to C3 suffices, while activation of 
the late complement components is necessary for the development 
of hemorrhagic necrosis. Clearance of bacteria, and phagocytosis 
of antibody sensitized erythrocytes was unimpaired in C6 deficient 
rabbits (Rother and Rother, 1965; Rother et al, 1966a), which 
evidently shows that complement-dependent functions up to C5 are 
normal. This is also supported by the finding that anaphylatoxin 
generation and histamine release were the same for normal and C6 
deficient rabbit serum (Giertz et al, 1964) . Nephrotoxic serum 
nephritis could be induced in C6 deficient rabbits and had the 
same characteristics as in normal rabbits (Rother et al, 1966b; 
1967). Reports regarding the cellular immune reactivity in C6 
deficient rabbits are contradictory. Delayed hypersensitivity was 
found to be absent in one study (Volk et al, 1964), whereas it 
was completely normal in another (Biro, 1966). Equally contro­
versial findings have been reported on allograft rejection, that 
was impaired in a study by Volk et al, 1964 but found to be normal 
in another study (Biro, 1966) . As already mentioned slight dis­
turbances in the clotting system of C6 deficient rabbits have been 
found. 
2.5.3. Relation between complement and the major histocompatibili­
ty complex 
In man the inheritance of a number of isolated complement 
deficiencies is linked to the HLA-system (reviewed by Jersild et 
al, 1976; and Rittner, 1976). This linkage has been shown for C2, 
C4 and probably C8 deficiency. C2 deficiency which is the most 
frequently occurring complement deficiency, even shows linkage 
with two particular haplotypes (AW25, B19, DW2 and AIO, B18, DW2). 
A number of other complement deficiencies (Clr, cT.INH, C6 and 
probably C5) does not segregate with HLA. Furthermore the electro-
phoretic polymorphism that has been found for factor В is linked 
to HLA. By contrast a comparable polymorphism of factor C3, shows 
no linkage to HLA. 
Also in the mouse a correlation has been found between H-2 
haplotype and hemolytic complement activity (Demant et al, 1973). 
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The genes controlling complement activity are mapped in the S-
region of the H-2 complex. Initially it was found that some mouse 
strains had high concentrations of a certain serum protein (called 
Ss-protein) and others showed consistently lower levels. This 
characteristic was controlled by the S-region in the H-2 complex. 
In 1975 Lachmann et al demonstrated that the product of this S-
region was complement factor C4. Furthermore, there is evidence 
that at least one gene within the H-2 complex influences C3 
levels, but also one or more genes are involved that are not 
coded for by H-2 (Ferreira and Nussenzweig, 1975). Recently it 
was shown that not only variation in levels of C4 but also CI and 
C2 levels are governed by the S-region, since mice with the Ss 
high genotype have higher functional levels of CI, C4 and C2 than 
strains of the Ss low genotype (Goldman and Goldnan, 1976). The 
only known complement deficiency in mice, C5, is coded for by a 
single gene which is not located within the H-2 complex (Herzen­
berg et al, 1963). A further relationship between H-2 and comple­
ment is found in its influence on C3b receptors on lymphocytes. 
Complement can trigger a number of cellular responses via the C3b 
receptor present on various cells. The density of these C3b 
receptors on the lymphocyte membrane is controlled by two genes, 
and one of these is linked to H-2 (Gelfand et al, 1974). 
In conclusion we can say that there is growing evidence that 
especially the early components of complement both in man and in 
mice are controlled and influenced by genes of the major histo­
compatibility complex (MHC). Within the MHC also genes (SD and 
la) are located that code for several responder and stimulator 
characteristics of the immune response. Thus, there seems to be 
a functional relationship between immune recognition, mediation 
and response which is governed by a set of closely linked genes 
on the chromosomal region of the MHC. 
Addendum (to page 27): Recently it was convincingly demonstrated 
that C3NeF is an autoantibody against СЗЬВЬ (Daha, M.R., Austen, 
K.F., and Fearon, D.T., J. Immunol. (1978) 120, 1389). 
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Chapter III 
PARTICIPATION OF COMPLEMENT IN GRAFT REJECTION 
A REVIEW OF THE LITERATURE 
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3.1. INTRODUCTION 
Organs and tissues transplanted across a histocompatibility 
barrier elicit as a rule an immune response directed against the 
graft, which in most instances results in its destruction. This 
process may be mediated by cells that are cytotoxic to the graft 
(cellular immunity) or it can be initiated by antibodies speci-
fically directed against the graft antigens (humoral immunity). 
Which of these reactions will occur or will predominate depends 
on a host of variables such as the animal model, the type of allo-
graft, the presence of specific presensitization, or the concomi-
tant use of immunosuppressive treatment. 
The rejection of first set allografts in unmodified recipients 
is predominantly cellular, although signs of humorally mediated 
destruction (vascular lesions, granulocyte invasion, platelet 
aggregation, and fibrin deposits) can be found (Carpenter et al, 
1976). However, if an individual is sensitized and has antibodies 
against the graft, then the destruction after transplantation is 
clearly a humoral process. Depending on the concentration of 
circulating antibody the graft shows signs of hyperacute rejection. 
This phenomenon occurs in primarily vascularized grafts in 
several experimental systems and also in human transplantation. 
It is most dramatically illustrated by the grafting of a human 
kidney to a recipient who has circulating antibodies against the 
HLA-antigens of the donor. Within minutes after restoration of 
the vascular connections a violent and rapid destruction occurs. 
(Kissmeyer-Nielsen et al, 1966; Williams et al, 1968; Patel and 
Terasaki, 1969) . Comparable events take place in first set, 
primarily vascularized xenografts, where rejection is caused by 
naturally existing antibodies against the graft (Perper and 
Najarían, 1966; Giles et al, 1970; Rosenberg et al, 1971). 
The rejection of skin-grafts is somewhat different from that 
of other organ grafts, since in both first- and second set grafts 
cellular rejection has already developed before vascular con-
tinuity and consequent accessibility to humoral antibodies are 
established. 
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In certain experimental models humorally mediated graft des-
truction can be induced by the passive administration of anti-
bodies. Klassen and Milgrom (1971) and Holter et al (1972) 
induced hyperacute rejection of kidney allografts in rabbits by 
injection of antidonor serum. In this kind of experiments skin 
grafts again react somewhat differently, since they become only 
sensitive to the destructive action of antibodies after the graft 
has become vascularized, which occurs 4-5 days after transplanta-
tion (Gerlag et al, 1975). To study antibody mediated rejection 
of skin grafts cellular rejection has to be prevented by immuno-
suppressive treatment (neonatal thymectomy, anti lymphocyte serum). 
In such systems it has been shown that administration of anti-
bodies can indeed induce acute rejection of both xenografts and 
allografts of skin (Winn et al, 19 73; Baldamus et al, 19 73; Koene 
et al, 1973). 
The tissue injury induced by antibodies is a consequence of 
the activation of secondary mediator systems of which the comple-
ment system is the most important. Activation of the complement 
sequence not only generates a number of immunobiological acti-
vities important for the inflammatory reaction, but can also 
trigger other effector pathways such as coagulation and kinin 
generation (see chapter 2). Since this study focuses on the role 
of complement in antibody mediated graft destruction we will here 
review the relevant literature concerning its participation in 
the rejection process. In the subsequent section we will discuss 
the literature concerning the participation of antibodies and 
complement in the rejection of various grafts as studied by 
immunofluorescence techniques. The following section deals with 
the reports of the absence of destruction in experimental animal 
systems, if non-complement fixing antibodies are administered. 
The literature in which complement activity is measured during 
graft rejection is also reviewed, and finally attention will be 
given to graft experiments in recipients with congenital comple-
ment deficiency, or experimental complement depletion. 
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3 . 2 . IIIMUNOFLUORESCENCE STUDIES OF GRAFTS 
By immunofluorescence techniques complement components, 
particularly C3 and Clq, can frequently be demonstrated in asso-
ciation with IgG and IgM m rejected kidney allografts both m 
man(Porter et al, 1968; McKenzie and Whittingham, 1968; HcPhaul 
et al, 1970; Andres et al, 1970) and in experimental animals 
(Lmdquist et al, 1968; Pbbas et al, 1974). The presence of these 
deposits does not by itself mean that these immunoglobulins and 
complenent have participated in the allograft rejection. However, 
their pathogenetic role is supported by a number of observations. 
These deposits in the glomerular capillaries are frequently found 
at sites where active destruction of the graft occurs and where 
the density of HLA antigens is maximal (Sijbesma et al, 1974) . 
Immunoglobulin eluates of these grafts react m vitro with donor 
cells (Hager et al, 1964; Hampers et al, 1967; Goldman et al, 
1971; Pedersen and Morris, 1974) or, alternatively, produce a 
lesion indistinguishable from rejection when injected into ani-
mals of the donor strain (Spong et al, 1968). Furthermore it was 
found that deposits of IgM and C3 in vessel walls in one hour 
biopsies correlated in 89% of the cases studied with 1 month 
graft failure, while, if these deposits were absent, only 11% of 
the grafts failed after one month (Tourville et al, 1977). 
Although it is likely that similar mechanisms play a role in 
the humoral destruction of skin grafts, this cannot be substanti-
ated, since reports on immunofluorescence studies of such grafts 
are lacking. 
3.3. PREVENTION OF COMPLEMENT FIXATION 
A number of experiments is reported which suggest that des-
truction cannot occur if the administered antibodies are unable 
to activate complement. This was found with F(abl)2 fragments of 
antibodies and with antibodies or antibody subclasses that do not 
or very poorly fix complement. These preparations can even block 
the destructive action of complement fixing antibodies by their 
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prior binding to the antigenic target. Thus, allografts perfused 
with donor specific F(abl)2 antibodies prior to transplantation, 
did not show acute rejection after transplantation in specifically 
sensitized monkeys (Kobayshi et al, 1972; Habal et al, 1973) or 
rabbits (Holter et al, 1973). In experiments with rat skin grafts 
in mice Winn and coworkers (1973) found that injection of F(ab,)2 
fragments of mouse anti rat serum did not induce acute rejection 
in contrast to intact antibodies, which gave rise to a violent 
humoral destruction. Moreovor, if F(ab1)2 was given prior to the 
intact antibodies the rejection process could be blocked. Similar 
results were found in our laboratory in an allogeneic skin graft 
model (Capei et al, 1979). Results analogous to those with F(ab,)2 
fragments were found with fowl-antibodies which do not fix 
mammalian complement e.g. chicken anti rat serum in rat skin grafts 
in mice (Winn et al, 1973), and with non-complement-fixing 7S Igl 
mouse alloantibodies in skin allografts in mice (Jansen et al, 
1975) . 
These studies convincingly demonstrate that complement acti-
vation plays an important role in graft destruction by passively 
administered antibodies. 
3.4. MEASUREMENT OF COMPLEMENT ACTIVITY DURING GRAFT REJECTION 
Another approach to determine whether complement is involved 
in graft rejection, is the measurement of total complement acti-
vity (CH50 titer) and the determination of isolated complement 
factors with functional assays or with immunochemical methods 
(radial immunodiffusion assay) during graft rejection. However, 
interpretation of the results is difficult for a number of reasons. 
Certain complement factors can already be decreased while the 
CH50 titer is still unaltered. Furthermore, the activity found 
is the resultant of synthesis, catabolism, and tissue distribution. 
Thus, a decrease in complement activity does not by itself mean 
that there exists an accelerated catabolism, while alternatively 
increased catabolism may go undetected when there is also an in-
crease in synthesis. Some complement factors react as acute phase 
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TABLE I. Complement activity during graft réfection 
Author Transplantation model 
Grafted organ Recipient species 
Complement alterations 
A. ALLOGRAFT EXPERIMENTS 
A.l. Animals 
Simonsen, 1953 
Guinea et al, 1964 
Gewürz et al, 1966 
Coppola and Villegas, 1967 
Rother et al, 1967b 
Coppola et al, 196Θ 
Glovsky et al, 1973 
Kux et al, 1973 
kidney 
skin 
kidney 
skin 
skin 
skin 
skin 
kidney 
dog 
rat 
dog 
guinea pig 
rat 
guinea pig 
guinea pig 
rabbit 
no changes 
no changes (neither in first- nor in 
second set grafts) 
no changes 
depression of CH50 titer until 
rejection was complete 
no changes 
depression of CH50 and C3 up to C9, 
C2 levels unaltered 
no changes 
intrarenal complement consumption 
(arterio-venous differences in CH50) 
A.2. Human 
Guinea et al, 1964 kidney slight reduction of CH50 titer, more 
pronounced reduction of C2 
Austen and Russell, 1966 
Gewürz et al, 1966 
Carpenter et al, 1967 
Carpenter et al, 1969 
Shehadeh et al, 1970 
Kux et al, 1974 
Fearon et al, 1977 
Ooi et al, 1977 
kidney 
kidney 
kidney 
kidney 
kidney 
kidney 
kidney 
kidney 
nan 
man 
man 
man 
man 
man 
C2 depression 
C2 and CH50 depressed in cases with 
"accelerated" rejection 
initial rise, followed by a depression 
of C3 
hypercatabolism of C4 and C3 
initial rise of C3 and C4, later on 
depression 
intrarenal complement consumption 
indicative for subsequent rejection 
modest depressions of factor В and 01H 
depression of factor C3 and C4 
B. XENOGRAFT EXPERIMENTS 
Gewürz et al, 1966 rabbit kidney 
sheep kidney 
dog 
dog 
depression of CI, C4, C2, C3 and CH50 
depression of CH50 
Table II. Influenae of congenital complément def-iciency or complement devletion on allograft survival 
Author Transplantation model 
Grafted 
organ 
Recipxent 
species 
Presensiti-
zation 
Method of decomple-
nentation or defi-
cient factor 
Effect on graft sur-
vival 
Ä. COMPLEMENT DEPLETION 
A.l. Fvrst-set grafts 
Fuji et al, 1966 
Gewürz et al, 1967 
Pepys, 1972 
Glovsky et al, 1973 
A.2. Second-set grafts 
Maillard and Zarco, 1968 
Dempster and Brown, 1970 
Kux et al, 1971 
skin 
kidney 
skin 
skin 
skin 
skin 
dog 
chicken 
mouse 
guinea pig 
guinea pig 
skin 
kidney 
kidney 
rat 
dog 
dog 
sodiumcopper-
chlorophyllin 
CoVFb) 
С о VF 
CoVF 
CoVF 
fumaropimaric acid 
slight prolongation 
no effect 
no effect 
prolongation during 
C3 depression 
c) 
prolongation of MST 
from 8.1 to 10.6 days 
no effect 
skin grafts CoVF 
skin graft CoVF 
kidney graft citrate intra-
artenally 
Kobayashi et al, 1970 kidney monkey skin grafts CoVF 
no effect 
no effect 
prolongation in 50%, 
no rejection in 50% 
during citrate in­
fusion 
no effect 
Thomas et al, 1977 kidney rabbit 
Whittum and Lindquist, 1977 heart rat 
B. COMPLEMENT DEFICIENCY 
Volk et al, 1964 skin rabbit 
Crisler and Frank, 1965 
Caren and Rosenberg, 1965 
Biro, 1966 
skin 
skin 
skin 
mouse 
mouse 
rabbit 
Rother et al, 1967a skin rabbit 
Salerno, 1969 spleen cells mouse 
Weitzel and Rother, 1970 skin mouse 
a) induction of donor specific antibodies 
b) CoVF = cobra venom factor 
c) MST = median survival time 
skin grafts CoVF 
skin grafts CoVF 
C6 
none 
none 
skin grafts 
C5 
C5 
C6 
C6 
none 
none 
C5 
C5 
no rejection during 
complement depletion 
prolongation of MST 
from 1.04 to 66 hours 
delayed rejection in 
50%, graft acceptance 
in 50% 
no effect 
no effect 
no effect on first, 
second and third 
set grafts 
no effect in 50%, 
prolongation in 35%, 
acceptance of graft 
in 15% 
no effect 
slight prolongation 
reactants, and can be raised by a number of non specific stimuli. 
On the other hand complement factors can be lower as a consequence 
of immunosuppressive treatment with prednison (Atkinson and Frank, 
1973; Sneiderman and Wilson, 1975), during infection, and in 
uremic patients (Kult et al, 1974). 
It is therefore not surprising that on considering the litera-
ture concerning complement activity during graft rejection one 
finds contradictory results. The observations are summarized in 
table 1. 
In experimental allografts in animals in most instances no 
changes in complement activity are found, which is in agreement 
with the observation that first-set allografts are predominantly 
rejected by cellular mechanisms. In all reports on clinical trans-
plantation, however, a decreased complement activity has been 
found, especially of factor C2. There is no proper explanation 
for this difference. Possibly this observed difference is due to 
the fact that in clinical situations attempts are made to treat 
the rejection, which is not done in the reported experimental 
animal systems. Treatment of rejection in man consists mainly of 
increasing the dosis of corticosteroids and it has been shown 
that these drugs, especially in high doses, depress the levels of 
all complement components (Atkinson and Frank, 1973). A further 
argument for this might be that in most instances there is a 
delay between the onset of clinically diagnosed rejection and the 
decrease of complement levels. However, not all complement altera-
tions during graft rejection can be contributed exclusively to a 
decreased synthesis since Carpenter et al (1969) found an in-
creased catabolism of radiolabelled C4 and C3 during rejection. 
It is also possible that humorally mediated rejection is more 
important in renal allografts in man because the immunosuppressive 
therapy tends to suppress cellular immunity more strongly than the 
humoral response (Russell and Winn, 1970). As stated above, immuno-
suppression was not used in the reported animal systems. 
During the rejection of primarily vascularized xenografts in 
animals a clearcut and impressive decrease in complement activity 
has been observed. We have found analogous results in a xenogeneic 
skin graft system and these will be presented in chapter 7. 
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3.5. INFLUENCE OF COMPLEMENT DEPLETION OR CONGENITAL COMPLEMENT 
DEFICIENCY OF THE HOST ON ALLOGRAFT SURVIVAL 
The best method to prove participation of complement in graft 
rejection, is trying to influence graft survival by manipulation 
of the host's complement system. For this purpose cobra venom 
factor (CoVF) has been mostly used. CoVF is a factor from certain 
snake venoms that, via activation of the alternative pathway, 
induces a stable C3 convertase, which is not susceptible to the 
control mechanisms. It therefore leads to continuous C3 cleavage 
and induces C3 depletion (Cochrane et al, 1970). 
The results reported in the literature concerning complement 
depletion and graft rejection are rather confusing (see table 2). 
For first set allografts three authors (Fuji et al, 1966; Pepys, 
1972; Glovsky et al, 1973) report prolongation of graft survival, 
while Gewürz et al, 1966, and Glovsky et al, 1973 did not find 
any delay in rejection. At first sight it is surprising that in 
second set grafts, where humoral rejection is generally more domi-
nant, three of six authors do not find prolongation after comple-
ment depletion of the recipients. 
Also, when recipients with congenital complement deficiencies 
are used, almost all authors find an unchanged rejection pattern. 
The reason for this becomes however clear, if one realizes that 
all authors except one made use of skin grafts in their experi-
ments. As we already mentioned, humoral rejection is only seen in 
skin grafting experiments if the cellular immune response is 
suppressed until vascular connections between graft and recipient 
are established. If no immunosuppression is given the rejection 
process will be predominantly cellular, and therefore not influenced 
by complement deficiency. Two authors (Volk et al, 1964; Rother 
et al, 1967a) reported prolonged survival of skin grafts, carried 
by C6 deficient rabbits, but they also had in their groups a 
number of animals that accepted their grafts indefinitely. This 
raises serious doubts whether there existed equal differences in 
histoincompatibility between all donors and recipients, and for 
this reason it must be questioned whether the observed prolongation 
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TABLE III. Influenae of complement depletion, or congenital complement deficiency on xenograft survival 
Author Transplantation model Method of deconple- Effect on graft survival 
Graft Recipient species mentation or defi­
cient factor 
A. COMPLEMENT DEPLETION 
Snijder et al, 1966 
Gewürz et al, 1966,1967 
L m n et al, 1970 
Moberg et al, 1971 
Kux et al, 1971 
Mejia-Laguna et al,1972 
Winn et al, 1973 
pig kidney 
rabbit kidney 
pig kidney 
pig kidney 
pig kidney 
dog kidney 
rat skin 
dog 
dog 
dog 
dog 
dog 
rabbit 
mouse 
CoVF 
CoVF 
aggregated IgG 
carrageenin 
citrate 
CoVF 
citrate 
CoVF 
CoVF 
prolongation from 9 to 123 m m . 
prolongation from 5 to 72-150 min. 
prolongation from 5 to 22-90 min. 
prolongation from 5 to 51 m m . 
20 fold prolongation 
prolongation from 5 to 30-60 m m . 
no rejection during citrate infusion 
prolongation from 17 to 74 min. 
delayed or no rejection depending 
on the dose of CoVF and passively 
administered antibodies 
B. COMPLEMENT DEFICIENCY 
Mejia-Laguna et al,1970 dog kidney rabbit 
Winn et al, 1973 rat skin mouse 
C6 
C5 
no effect 
delayed rejection depending on the 
amount of passively administered 
antibodies 
was rightly attributed to the C6 deficiency. 
3.6. INFLUENCE OF COMPLEMENT DEPLETION OR CONGENITAL COMPLEMENT 
DEFICIENCY OF THE HOST ON XENOGRAFT SURVIVAL 
In the studies reported (see table 3) acute rejection could be 
prevented by depletion of the complement system (in most instances 
C3 depletion). However the protection was not complete, since 
rejection eventually occurred m all cases. 
The few studies that were performed in animals with congenital 
complement deficiencies suggest that rejection of xenografts 
occurred in spite of a deficiency in the terminal complement com-
ponents. Thus, in a study with dog kidneys transplanted to C6 
deficient rabbits the rejection was the same as in normal rabbits 
(Me^ia-Laguna et al, 1970). Comparable results were obtained by 
Winn et al (1973) with established rat skin grafts m C5 deficient 
mice. With high dosis of mouse anti rat antiserum humoral destruc-
tion of the grafts could be induced. 
3.7. CONCLUSION 
On reviewing the literature we have come to the conclusion 
that complement clearly is involved in the rejection of xenografts. 
This is supported by the histologic findings in rejected xeno-
grafts. These show the characteristic picture of an Arthus reac-
tion, that is known to be complement dependent. From the results 
of xenograft studies in complement deficient recipients it seems 
likely that not all complement factors are necessary, and that 
generation of factors C3a and C5a, with their biologic important 
functions, suffices to cause graft damage. However, complement 
inhibition did never prevent a rejection, which suggests that 
complement independent processes are also involved. 
The literature concerning complement participation in allo-
graft rejection is contradictory. With regard to skin allografting 
in non-immunosuppressed animals most of the available data indi-
cates that humoral rejection, and thus complement involvement, is 
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of minor importance. 
The reports on primarily vascularized allografts in animals 
do not allow a definite conclusion, although the results in sen-
sitized recipients make it likely that humoral mechanisms contri-
bute to graft damage. 
In human kidney transplantation complement participation is 
probably of greater importance than in analogous experimental 
animal systems. Most rejected human kidneys show characteristics 
of antibody mediated graft destruction. This is possibly due to 
the fact that the recipients are treated with immunosuppressive 
agents which better suppress cell-mediated than humoral immunity. 
Manipulation of the complement system might, therefore, be a means 
to interfere with this destructive process. 
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SUMMARY 
Acute antibody-mediated rejection (AAR) of mouse skin allografts was studied in 
nine donor-recipient combinations with increasing histoincompatibihty ranging from 
an Η-Y to a complete H-2 plus non-H-2 disparity AAR was induced by the injection of 
specific alloantiserum along with a heterologous complement on day 7 after grafting 
Sera from rabbits, guinea pigs, and from a human volunteer were used as complement 
sources The recipients were treated with antilymphocyte serum on days 0, 2, and 4 to 
postpone cell-mediated rejection With increasing histoincompatibihty the mean sur­
vival time of untreated grafts decreased, the in vitro cytotoxic activity of the alloanti­
serum rose, and AAR could be induced with lower amounts of antiserum The higher 
efficiency of rabbit complement compared with guinea pig complement and human 
complement, that is known to exist in in vitro cytotoxicity, was also found in vivo 
Rabbit complement could induce AAR m combination with relatively weak histoin­
compatibihty (H-2K, H-2D, or non H-2 differences), where guinea pig complement and 
human complement were ineffective All three complement species elicited AAR if 
there was a disparity for H-2D plus non-H-2, H-2K plus non-H-2, H-2, or H-2 plus non-
H-2 The rules for immunogemcity of the different histocompatibility loci as they have 
been described for cell-mediated graft destruction also apply to this humorally me­
diated rejection process 
Since the first description of hyperacute re­
jection of human renal allografts (14), there 
has been a growing interest in the role of hu­
moral antibodies in graft destruction Primar­
ily, vascularized grafts are clearly susceptible 
to antibody-mediated damage, not only in man, 
but also in many experimental animals (2) 
The role of antibody in the destruction of skin 
grafts is more controversial Until recently it 
was assumed that skin grafts were resistant to 
antibody and that their destruction was 
brought about by cellular mechanisms How­
ever, several models have now been described 
In which antibodies are responsible for acute 
skin graft destruction Jooste and Winn ill) 
and Jooste et al (12) were able to induce acute 
1
 This work was supported by grants from the 
Netherlands Foundation of Medical Research 
(FUNGO) and from the Netherlands Kidney 
Foundation 
destruction of rat skin grafted onto immuno-
suppressed mice by the injection of mouse anti-
rat serum or of rat antiserum specifically di­
rected against the alloantigens of the donor In 
a subsequent study they showed that allogeneic 
rat skin grafted onto immunosuppressed rats 
could also be destroyed by alloantibody (11) 
Furthermore, they found evidence that the fi­
nal damage is caused by the activation of 
mouse complement (27) In a previous report 
we have shown that mouse skin allografts can 
be successfully destroyed by alloantibody pro­
vided a heterologous complement, ι e , rabbit 
complement, is administered along with the 
antiserum (16) Apparently the mouse endoge­
nous complement is inefficient in this situation 
and this correlates well with the low efficiency 
of this complement species in in vitro cytolysis 
systems (9) In the mouse the study of acute 
rejection of allografts by antibody is of particu-
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lar interest because its many inbred strains 
permit detailed genetic analysis The genetics 
of cell-mediated skin grail destruction has been 
extensively studied in this species, and it has 
become evident that there exists a close rela­
tionship between the time required for graft, 
destruction and the extent of histocompatibility 
differences (7,20,21) Our model of acute anti­
body-mediated, complement-dependent rejec­
tion (AAR) enabled us to study whether an 
analogous correlation also exists for humorally 
mediated allograft damage To this end we 
have studied the occurrence of AAR in nine 
donor-recipient combinations with increasing 
histoincompatibihty 
Complement activation is necessary for 
AAR and whether this occurs seems to depend 
upon the degree of histoincompatibihty be­
tween donor and recipient The studies of 
Jooste and Winn ill) and Jooste et al (12) 
have shown that mouse complement can be 
come activated in a xenogeneic system and 
also in certain allogeneic combinations In our 
system with limited antigenic differences, 
rabbit complement was required for the de 
struction of allografts by antibody Analogous 
results have been obtained in renal grafts in 
rats August ra t kidneys in AS recipients 
were not destroyed by antibody, unless guinea 
pig complement was administered with the 
antiserum (6) On the other hand, DA grafts 
in Lewis recipients, which represent a 
stronger histoincompatibihty than August to 
AS, could be destroyed by administration of 
antibody alone (5) Differences in efficiency 
of various complement species have also been 
observed in many in vitro cytolytic systems 
(4, 9, 10, 17, 26) With mouse alloantibody 
rabbit complement is superior to guinea pig 
complement, while rat and mouse complement 
hardly ever induce complement-dependent 
cytotoxicity (9, 17) The second aim of this 
study was, therefore, to test several comple­
ment species rabbit complement (RC), guinea 
pig complement (GPC), and human comple­
ment ( H O , for their ability to evoke AAR of 
skin grafts m combinations with increasing 
histoincompatibihty and to compare these 
results with the complement activity in in 
vitro cytotoxicity 
MATERIALS AND METHODS 
Mice Inbred lines of BIO D2/new Sn, A/HeJ, 
BIO Br, and BIO LP mice were originally ob­
tained from the Jackson Laboratory, Bar Har­
bor, Maine C57BL6/Rij mice were obtained 
from the Radiobiological Institute TNO, 
Rijswijk, The Netherlands BALB/c and DBA/2 
mice were originally obtained from the Na­
tional Institutes of Health, Bethesda, Mary­
land CBA/J mice were bought from a commer­
cial animal farm (G L Bomholtgard Ltd, Rij, 
Denmark) 
In our animal laboratory these mouse strains 
were kept by continuous brother-sister mat-
ings (C57BL6/R1J x A/HeJJF, (B6AF1) hybrids 
were raised in the laboratory All of these 
strains were analysed with various monospe­
cific alloantisera (obtained from National Insti 
tutes of Health, Bethesda, Maryland) against 
private and public specificities of the H-2 com­
plex to rule out the possibility of differences 
between the presumed and real haplotypes of 
these strains 
Selection of donor-recipient combination In­
formation concerning H 2 haplotypes, H-2 re­
combinants, and non H 2 differences used in 
selecting donor-recipient combinations came 
from Demant (3), Graff and Bailey (7), Graff 
and Snell (8), and Klein (15) The nine combi­
nations chosen and their antigenic differences 
are listed in Table 1 The first three combina­
tions comprise only non-H-2 differences in an 
increasing number Combination 3 represents 
disparity of almost all known non H 2 loci 
Combinations 4, 6, and 8 differ in the H-2D 
region, the H 2K region, and the complete H-2 
complex, respectively Since C57BL10 congenie 
strains served as donors on C57BL6 recipients 
there is also a difference at the H 9 locus (8) 
This difference, however, is weak so that there 
will be no cumulation of immunogemcity be­
tween the non-H-2 and H-2 differences ( 7) Fur­
thermore, absorption of the C57BL6 anti-
B10 D2 serum with C57BL10 cells did not 
change the titer of the antiserum in vitro For 
practical reasons we therefore consider these 
combinations as differing only at the H 2 com­
plex In combinations 5, 7, and 9 there exists 
not only a difference at the H 2 complex (H-2D 
end, H 2K end, and complete H-2, respectively), 
but there are also a number of non-H-2 differ­
ences 
Production of alloantisera Alloantisera 
were prepared by injecting female recipient 
mice at weekly intervals, ι ρ , with a suspen­
sion of approximately 5 χ IO7 donor lymphoid 
cells in complete Freund's adjuvant For the 
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TABLE 1. Antigenic differences of strain combinations used 
Combi­
nation 
1 
2 
3 
4 
5 
6 
7 
θ 
9 
Donor 
(M) 
B6AF, (M) 
C57BL6 
B 1 0 D 2 
BIO Br 
A/HeJ 
B10.D2 
DBA/2 
B 1 0 D 2 
DBA/2 
• Only "classic" H-2 
4
 According toU). 
Recipient 
(F) 
B6AF, (F) 
BIO LP 
BALBc 
B6AF, 
CBA/J 
B6AF, 
B6AF, 
C57BL6 
C57BL6 
specificities 
Haplotype 
a χ b -> a χ 6 
ь — b 
d->d 
k — a χ 6 
0 - * 
d - » α χ 6 
d -» a χ 6 
< i - > 6 
H-2 coi 
Private 
-
H-2D 32 
II-2D 4 
H.2K 31 
H-2K 31 
H-2K31 
H-2D4 
H-2K 31 
H-2D4 
nplex 
Specifici ties" 
Public 
-
H-2 6, 10, 13, 14, 27, 
29, 35, 36, 40, 41, 
43.44 
H-2 34 
H-2 34 
H-2 3 ,8 , 10, 13,34, 
4 1 , 4 2 . 4 3 , 4 4 , 4 7 , 4 9 
H-2 3, 8, 10, 13, 34, 
41, 42, 43, 44, 47, 49 
28, 
42, 
40, 
40, 
are listed Specificties 34 and 47 are probably la specific 
Non-H-2 loci 
H-Y 
H-3, H-9, H-13 and probably 
two other* 
H-1.H-3,H-4,H-7,H-8,H-
' 13, H-15, tlm 30, Il-X 
H-9 
H-I, H-4, H-7, H-9 and prob­
ably also H-3 and H-8 
H-9 
HI, H-3, H-4, H-8, H-13 
H-9 
HI, H-3, H-4, H-8, H-13 
ι ties 
anti-H-Y antiserum B6AF, sperms cells were 
used instead of lymphoid cells. After five injec­
tions most animals developed ascites and could 
be tapped every 1 to 2 weeks. The production of 
several weeks was pooled and, before use, all 
antisera were heated at 56 С for 45 min and 
sterilized by passing through a sterile 0.20-Γημ 
filter. The cytotoxic titer of the ascites fluid was 
the same as the titer in the serum of these mice. 
Antisera were stored at -20 С. 
Anhlymphocyte serum (ALS). ALS was pre­
pared by a s.c. injection of 5 to 8 χ IO7 C57BL6 
lymphoid cells (thymus and mesenterial lymph 
nodes) in complete Freund's adjuvant into a 
goat. This priming dose was followed by weekly 
i.v. boosters of the same number of C57BL6 
lymphoid cells. The animals were bled 1 week 
after the fourth immunization, and the serum 
was heated at 56 С for 45 min and absorbed once 
with C57BL6 RBC (5 volumes of serum/1 vol­
ume of packed cells). This ALS was not toxic to 
the recipients if injected i.p. 
Complement. Fresh or fresh frozen sera from 
New Zealand White rabbits, random-bred SPF 
Albino guinea pigs, and from a human volun­
teer were used as sources of complement. Be­
fore use all sera were tested for toxicity in vitro 
(a 1/4 dilution should give less than 10% cytoly-
sis of the various donor lymphocytes) and in 
vivo by injecting 0.5 ml of serum i.v. Blood was 
obtained in rabbits and guinea pigs by cardiac 
puncture, in the human by venous puncture. 
After clotting for 45 min at room temperature 
and centnfugation, the serum was divided in 
aliquots of 0 5 ml and, if not immediately used, 
stored at -30 С Complement was used only 
once after thawing. 
Serology. Cytotoxic tests were performed us­
ing the trypan blue exclusion test. Except in 
the B6AF! female anti-male antiserum, where 
B6AF, sperm cells were used, spleen cells were 
used as the targets. They were prepared free of 
RBC with Tris-NH,C1. One hundred microli­
ters of cells (5 x 105) in Hank's balanced salt 
solution (BSS) were incubated with equal vol­
umes of antibody dilutions and RC, GPC, or HC 
(diluted 1/4) for 30 min at 37 С The titer was 
defined as the antiserum dilution giving 50% 
lysis. All tests were performed in triplicate and 
the following controls were performed: (1) cell 
control, 100 μ\ of cells in 200 μΐ of Hank's BSS; 
(2) antibody control, 100 μΐ of cells, 100 μΐ of 
undiluted antiserum, and 100 μΐ of Hank's 
BSS; and (3) complement control, 100 μΐ of 
cells, 100 μΐ of complement, and 100 μΐ of 
Hank's BSS. In these controls cytolysis should 
not exceed 10%. 
Skin grafting technique. Donor tail skin was 
grafted onto the flank of the recipients by a 
modification of the "fitted graft" technique. In­
stead of plaster bandage we used a band-aid to 
cover the graft. In all experiments except in 
combination 1, donor and recipient were fe­
males and between 6 to 10 weeks old. The band-
aid was removed on the 6th day after transplan­
tation. The fate of the grafts was followed by 
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daily macroscopic inspection The grafts were 
considered to be rejected when no viable epider-
mis remained The median survival time 
(MST) and the standard deviations were calcu-
lated according to the method of Litchfield (ÍS) 
Hyperacute rejection studies All experi-
ments were performed on well established 
grafts that showed no signs of rejection In all 
combinations, except combinations 1 and 2, the 
survival of these grafts was prolonged by non-
specific immunosuppression with ALS (0 25 ml 
ι ρ ) on days 0, 2, and 4 after grafting Seven 
days after grafting, the mice received 0 01 to 2 0 
ml of alloantiserum directed against the donor 
antigens and 0 25 ml of RC, 0 5 ml of GPC, or 
0 5 ml of HC by ι ν injection through the tail 
vein The choice of the volumes of complement 
was based on dose response studies in combina­
tion 8, where we found that these amounts 
provided excess of complement if injected with 
excess antibody Volumes of alloantiserum 
lower than 0 5 ml were given in an appropriate 
dilution in saline, with an end volume of 0 5 ml 
In each donor-recipient combination control ex­
periments were performed by injecting antise­
rum alone, complement alone, and 0 25 ml of 
RC with a particular for that combination non­
specific alloantiserum AAR was defined as the 
complete necrosis of the skin graft 24 to 72 hr 
after ι ν injection In most cases this process 
was completed within 48 hr 
Histological examination In the two combi­
nations where we did not see macroscopic signs 
of acute rejection, histological examinations 
were performed Vz, 2, and 8 hr after ι ν injec­
tion of alloantiserum and complement The 
skin graft and surrounding recipient skin were 
removed and fixed in 4% buifered formalin The 
paraffin sections were stained with hematoxy­
lin and eosin 
RESULTS 
Cytotoxic titers of alloantisera The titers of 
the various alloantisera are given in Table 2 In 
all cases we could detect cytotoxic antibodies, 
even in the three combinations with only non-
H-2 differences Antiserum 1 induced cytolysis 
of B6AF| sperm In antiserum 2, prepared 
across an H-3, H-9, and H-13 difference, we 
could demonstrate cytotoxic activity by increas­
ing the sensitivity of the test with the use of 
less target cells (W instead of 5 χ IO5) With 
many non-H-2 antigenic differences present, as 
is the case in combination 3, the antiserum 
became highly cytotoxic (i/128 with RC) 
Antisera produced across H-2 differences 
showed a gradual rise in cytotoxicity as the 
antigenic difference increased The titer was 
lowest with only an H-2D difference, higher 
with an H-2K difference, and highest when 
there was incompatibility for the whole H-2 
complex (antisera 4, 6, and 8) Addition of non-
H-2 differenceb to each of these H-2 differences 
(antiserum 5, 7, and 9) gave a further nse in 
cytotoxic activity with GPC and HC, whereas 
this increase was absent in the tests with RC 
The situation is somewhat special with antise­
rum 5, since this serum does not simply repre­
sent an extension of antiserum 4 with non-H-2 
antibodies The H-2D 32 difference of combina-
TABLE 2 Cytotoxic titers of alloantisera with different complement species 
Combination Alloantiserum 
B6AF, (F) anti-BSAF, 
BIO LP anti-C57BL6 
BALB/c anti-BIO D2 
B6AF, anti-B10 Br 
CBA/J anti-A/HeJ 
B6AF, anti BIO D2 
B6AF, anti-DBA/2 
C57BL6 anti-BIO D2 
C57BL6 anti-DBA/2 
(M) 
Cytotoxic titer 
RC GPC 
+° 
+ •• 
1/128 
1/16 
1/512 
1/512 
1/512 
1/3072 
1/4096 
ND» 
ND 
+ « 
0 
1/16 
1/12 
1/32 
1/64 
1/128 
HC 
ND 
ND 
+ « 
0 
1/16 
1/8 
1/32 
1/48 
1/96 
α
 Cytolysis of sperm cells up to 90% in dilution 1/2 
* ND, not done 
r
 Cytolysis up to 60% above controls in dilution 1/2, with lower number of target cells (10 /^100 μΐ), controls 
less than 10% lysis 
'* Cytolysis up to 30% in dilution 1/2 
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tion 4 has been replaced here by an H-2D 4 
difference, which is more immunogenic (20) 
and, furthermore, many public specificities are 
introduced This could explain the relatively 
high rise in cytotoxic activity of antiserum 5 as 
compared with antiserum 4 
In accordance with previous studies (4,9,10, 
17), we found that in all instances the cytotoxic­
ity was highest if measured with RC as com­
pared with GPC or НС To test the activity of 
mouse complement, each test was also per­
formed with fresh recipient mouse serum, but 
cytolysis clearly above control levels was never 
observed 
Acute antibody-mediated rejection The re­
sults are summarized in Table 3 Control grafts 
placed on recipients that received ALS survived 
with MST's ranging from 17 8 ± 1 2 to 33 9 ± 
1 4 days Thus, in no case were there signs of 
rejection on the day of ι ν injection (day 7) and 
the following 3 days Not shown are the control 
experiments performed in each donor-recipient 
combination with administration of alloantise-
rum alone, RC, GPC, or HC alone, or nonspe­
cific alloantiserum along with RC In no case 
was AAR observed and the MSTs of these ex­
periments did not differ significantly from the 
MST's of the ALS-treated animals 
Non-H-2 differences (combinations 1, 2, and 
3) We were not able to induce AAR across an 
Η-Y barrier nor across an H-3, H-9, and H-13 
barrier In the B6AF, male onto female combi­
nation it was, however, possible to reduce the 
survival t ime of the skin grafts from 126 to 99 8 
days by administration of alloantiserum and 
RC Microscopic examination 11г, 2, and 8 hr 
after ι ν injection of antiserum and RC did not 
show any signs of rejection In the second com­
bination, C57BL6 onto BIO LP, where macro-
scopically no signs of rejection occurred, we 
found microscopically 2 hr elfter administration 
of antibodies and RC a slight increase of granu­
locytes in the blood vessels of the graft and in 
the surrounding tissues of the graft with focal 
extravasation of erythrocytes Eight hours 
after the injection, these rejection signs were 
already less extensive This suggests the induc­
tion of a reaction that was not severe enough to 
cause visible rejection of the graft When skin 
was grafted across a great number of non-H-2 
differences (combination 3), the MST of the 
untreated animals came into the range of 
TABLE 3 AAR of mouse skin allografts in strain combinations with increasing histoincompatibihty 
Combi 
nation 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Donor -» Recipient 
(M-.F) 
B6AF, (M) - B6AF, (F) 
C57BL6 — BIO LP 
BIO D2 -» BALB/c 
BIO Br - B6AF, 
A/HeJ - CBA/J 
BIO D2 ^ B6AF, 
DBA/2 -. B6AF, 
BIO D2 — C57BL6 
DBA/2 -> C57BL6 
MST in untreated (I) 
and immunosuppreseed 
(II) 
No of ani­
mals 
HO 
из 
112 
II 20 
no 
II 20 
110 
1110 
115 
II 18 
no 
ino 
no 
и i3 
115 
II 14 
animals" 
Days ± 
>120 
15 4 ± 
10 4 ± 
24 0 ± 
12 8 ± 
31 9 ± 
9 8 ± 
24 0:!: 
10 0 ± 
21 2 ± 
9 5 ± 
22 0 ± 
9 3 ± 
19 0 ± 
85 ± 
17 8 ± 
SD 
5 
1 
1 2 
RC 
Anti­
serum (ml) 
2 5" 
2 5" 
0 5 
10 
15 
10 
15 
0 01 
0 05 
0 01 
0 05 
0 01 
0 05 
0 005 
0 01 
0 005 
0 01 
b 
AAR' 
0/15 
0/8 
0/6 
0/11 
6/6 
0/12 
8/8 
0/6 
6/6 
0/6 
6/6 
0/6 
11/11 
0/8 
8/8 
0/8 
6/6 
JFC 
Anti 
serum (ml) 
15 
15 
05 
10 
15 
05 
10 
15 
2 0 
05 
10 
15 
0 01 
0 05 
0 01 
0 05 
ND' 
ND 
ъ 
AAR' 
0/7 
0/β 
0/7 
0/6 
7/7 
0/7 
0/8 
0/9 
0/6 
0/6 
0/6 
6/6 
0/5 
8/8 
0/5 
6/6 
HC' 
Anti 
serum (ml) 
15 
15 
15 
15 
15 
05 
05 
ND 
ND 
AAR' 
0/5 
0/5 
8/8 
0/8 
8/8 
10/10 
8/8 
" Immunosuppression by ι ρ injection of 0 25 ml of GAMLS on day 0, 2, and 4 after grafting 
6
 AAR was induced by ι ν injection of listed volumes of antiserum along with 0 25 ml of RC, 0 5 ml of GPC, or 0 5 ml of 
HC on day 7 after grafting 
r
 Number of mice that show complete graft necrosis within 24 to 72 hr after injection/number of mice tested 
d
 1 5 ml was given ι ν and 1 0 ml ι ρ 
' ND, not done 
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MST's of grafts acrctes an H-2 b a r n e r In this 
combination AAR could be induced with 1 5 ml 
of antiserum and RC Lower doses of antiserum 
did not cause AAR, although there was a de­
crease of several days in the MST of the skin 
grafts With GPC and HC no AAR could be 
induced 
H-2 differences (combinations 4, 6, and 8) 
Induction of AAR across an H-2D incompatibil­
ity was only possible with 1 5 ml of alloantise-
rum and RC, while across an H-2K incompati­
bility it was obtained with 0 05 ml of alloantise-
rum If there existed a complete H-2 complex 
disparity, the amount of alloantiserum neces­
sary for induction of AAR with RC was further 
reduced to 0 01 ml In this latter combination it 
was also possible to induce AAR with GPC and 
HC but the dose of alloantiserum had to be 
higher than with RC 
H-2 and non-H-2 differences (combinations 
5, 7, and 9) AAR with RC of skin grafted 
across H-2D plus non-H-2 differences or across 
H-2K plus non-H-2 differences was obtained 
with 0 05 ml of alloantiserum whereas only 0 01 
ml was necessary for rejection of a graft differ­
ing at the whole H-2 complex plus non-W-2 loci 
Thus, the introduction of non-H-2 differences 
did not lead to a lower amount of alloantibody 
necessary for AAR with RC The A/HcJ -» 
CBA/J combination formed an exception, but 
as already mentioned in this combination not 
only H-2 differences are introduced but there is 
also a change in the H-2 difference compared 
with BIO Br -> B6AF, For GPC and HC we 
found that the amount of alloantiserum re­
quired for AAR decreased when non-H-2 differ­
ences were introduced In BIO D2 onto BBAF, 
we could not induce AAR with 2 0 ml of alloan­
tiserum, but in the DBA/2 onto B6AF, combi­
nation 1 5 ml of antiserum given with GPC or 
HC was effective This must be the result of the 
cumulative effect of non-H-2 differences In the 
in vitro lymphocytolysis we observed a similar 
pattern The addition of non-H-2 differences to 
H-2 differences increased the cytotoxicity if the 
antiserum was titrated with GPC and HC, but 
the titer with RC did not change (Table 2) 
Figure 1 gives a graphical summary of the re­
sults of this study 
DISCUSSION 
Our results show that the sensitivity of skin 
grafts to the destructive effects of alloantibody 
and heterologous complement increases with 
the extent of antigenic differences between do­
nor and recipient In a combination with a few 
non-H-2 differences, we found only microscopic 
signs of tissue damage, even if a high amount of 
specific antiserum was administered In the 
combinations with H-2 differences, К end-in-
compatible grafts were more easily destroyed 
than D end-incompatible grafts, whereas with 
complete H-2 and non-H-2 differences a violent 
rejection could be induced with minimal 
amounts of antiserm This increase in sensitiv­
ity was accompanied by a gradual decrease in 
MST of the skin grafts in untreated animals in 
which rejection is presumed to be mediated 
mamly by cellular mechanisms The decrease 
in MST that occurs when the antigenic differ­
ences become greater has been described ear­
lier (7, 20, 21), and it has been shown in those 
studies that the MST can even be used as a 
measure for the degree of immunogemcity of 
the graft The rules of immunogemcity that 
have been found for these cellular immune 
responses (7) also apply to our model where the 
destruction is mediated by humoral mechan­
isms 
A second aspect that deserves to be men­
tioned is the finding that there were clear-cut 
differences in the activity of a given antiserum 
if tested with different complement species The 
lower in vitro activity of GPC compared with 
RC has been described by several authors (4,9, 
10,17) and is confirmed in this study Further­
more, we found that HC behaves more or less 
like GPC in this respect In all of the combina­
tions studied, we found similar differences in 
complement activity in vivo RC was always 
more active than GPC or HC These two latter 
complement species only did work in combina­
tions with strong antigenic differences The ar­
gument about the relationship between in vitro 
and in vivo complement activity extends to 
mouse complement This complement species is 
very inefficient in vitro, and was apparently 
not sufficiently activated in our in vivo system 
to induce antibody-mediated destruction 
The correlation between in vitro and in vivo 
activity raises the question whether the mecha­
nism of AAR is exactly the same as the in vitro 
cytolysis, or in other words, whether the com­
plement pathway has to become completely ac­
tivated to induce AAR Winn et al (27) found 
in their model, where mouse complement was 
the active complement, that in C5-deficient 
mice the process was delayed, while severe de-
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Minimal volume of 
a n t i s e r u m ( m l ) 
lo­
i s 
1 
O l 
0 05 
О 01 
• RC 
D GPC 
Ш не 
и 
(cytotoxic t i t e r ) ' 
of a n t i s e r u m 
4 0 9 6 -
2 0 4 8 
1024 -
512 -
256 
12Θ -
6 4 
32 
16 
8 -
4 -
2 -
<2 -
Histocom­
patibil ity 
barr ier 
Η-Y H-3 H-2D multiple H 2K H 2D H-2K 
H 9 non H-2 plus plus 
H-13 ηοπΗ2ηοπΗ-2 
H-2 H-2 
plus 
non H-2 
MST untreated 
animals (days) >126 15 4 12 8 10 4 10 0 9 8 9 5 9 3 8 5 
FIGURE 1 Acute antibody-mediated rejection in strain combinations with increasing histoincompatibil-
ity Relationship between MST of grafts in untreated recipients, in vitro cytotoxic titer of antiserum, and 
minimal amount of antiserum required to induce AAR with different complement species (RC, GPC, and 
HC) 
pletion of granulocytes could abolish rejection. 
They concluded from these observations that 
the role of complement is merely one of gener­
ating the chemotactic substances C3a and C5a 
Histological studies show that in our model 
similar mechanisms play a role, since we found 
earlier a dense accumulation of granulocytes in 
the graft after injection of antibody and comple­
ment (76) It is, however, not excluded that, in 
our experiments with heterologous comple­
ment, direct lysis of the graft attributable to 
complement activation beyond C5 played an 
important role. Further support for this as­
sumption stems from our unpublished findings 
that with complement from C6-deficient rab­
bits, antibody-mediated graft destruction could 
not be induced and that the destructive capac­
ity was reestablished after reconstitution of 
this serum with C6. It might be argued that C6 
also contributes to the leucotactic activity in 
the C567 complex (25), but there is evidence 
(23, 24) that the leucotactic property of C6-
deficient serum is unimpaired For the time be­
ing, this problem remains unresolved and 
awaits studies with sera that are deficient only 
in the terminal components of the complement 
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system, such as C9. 
In clinical transplantation little is known 
about the role of non-HLA differences in the 
acceptance of allografts There are a few reports 
of severe rejection episodes of renal grafts from 
HLA mixed lymphocyte culture-identical sib­
lings U9, 22). Kano et al. (13) reported that in 
recipients with a rejection of an HLA-identical 
kidney, antibodies could be detected against 
non-HLA antigens. From models in mice it is 
known that, if there exist multiple non-H-2 
differences, skin graft survival can be equival­
ent to that of grafts differing at the complete 
H-2 complex (7). In our study it was possible to 
induce AAR across only non-H-2 differences. 
These differences can, therefore, not only cause 
cellular graft rejection but can also be responsi­
ble for antibody-mediated graft damage. This 
phenomenon should be bome in mind when the 
antibody-mediated rejection in clinical trans­
plantation is studied. 
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J.H.M Berden, Ρ J.A. Capel and 
R.A.P. Koene 
Department of Medicine, Division of 
Nephrology, Sint Radboud Ziekenhuis, 
University of Nijmegen, Nijmegen 
The role of complement factors in acute antibody-
mediated rejection of mouse skin allografts* 
Established, Η 2 incompatible, mouse skin allografts are desiroyed in 
2 4 - 4 8 h by a single intravenous injection of specific alloantibody and 
heterologous complement (C) from rabbits (RC), guinea pigs (GpC) or 
humans (HC) Mouse complement (MC) itself is inefficient in this respect 
since grafts are not destroyed by the injection of antibody alone This is 
in keeping with the low efficiency of MC in in vitro cytolysis 
We have studied the role of different С factors in this model Two patterns 
were observed (a) Three C-deficient sera (GpC-R4, GpC-R3, RC-R6) 
showed neither activity m vitro (C-mediated lymphocytoloxicily in a 
trypan blue assay) nor did they induce graft destruction Activity in vitro 
and in vivo could be completely reconstituted with the appropriate С com­
ponent (b) Two C-deficient sera (GpC-R 1 and HC-R9) were inactive ш 
in vitro cytotoxicity but, nevertheless, induced destruction of the skin 
grafts if injected with antibody Thus, in vivo, the mouse seemed to provide 
the deficient factor, and this was confirmed by the observation that m vitro 
cytotoxicity could be reconstituted not only with the appropriate С com­
ponent, but alto with normal mouse serum The results show (hat the in­
efficiency of MC m vitro and in vivo does not reside in the factors CI or C9 
Furthermore, in our model С is activated via the classical pathway, and at 
least exogenous C4, C3 and C6 are required to induce acute antibody-
mediated graft destruction 
From the experiments with C6-deficicnt serum which has normal chemo-
tactic properties, it is concluded that activation of chemotactic factors 
with attraction of granulocytes is not sufficient to induce rejection, but 
that the activation of the membrane attack unit is required 
1 Introduction 
The rejection of skin grafts in the mouse is considered a 
primarily cellular immune event The antibody-mediated 
destruction of mouse skin allografts is of less importance, 
as is shown by the failure of passively administered allo-
antibodies to induce graft rejection [ I ] This is at least part­
ly due to the inefficiency of the mouse complement (MC) 
system We have previously shown that well-established 
H-2-incompatible allografts earned by immunosuppressed 
mice can be quickly (within 24 h) destroyed by an intravenous 
(ι ν ) injection of alloantiscmm together with rabbit comple­
ment (RC) [ 1 ] There are several arguments which support 
the assumption that the exogenous С is necessary for this 
antibody-mediated graft rejection First, the histology of the 
grafts shows the charactenstics of an Arthus reaction [ 1 ] 
which is known to be C-dependent Second, after inactivation 
of the С system, by heating, treatment with zymosan, carra-
[I 1873] 
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Abbrevia lions: AAR Acute antibody-mediated rejection ALS: Anti-
lymphocyie serum GpC· Guinea pig complement GVB++: Veronal-
buffered saline with gelatin, Ca++ and Mg++ Hanks' BSS. Hanks" 
buffered salt solution HC- Human С MC: Mouse С MST: Median 
survival time NMS: Fresh normal mouse serum RC* Rabbit С 
Ri С deficient in Cl R4· С deficient in C4 R3: С deficient in СЭ 
R6: С deficient in C6 R9: С deficient in C9 RSO Relative salt con­
centration SD. Standard deviation S RBC: Sheep red blood cells 
geenan or aggregated human IgG, the rabbit serum no longer 
induced acute graft destruction if injected with antibody [2] 
Third, acule rejection was only seen with C-fixing antibodies 
(7 S IgGj) and not with 7 S IgG l antibodies that do not fix 
с[з] 
Heterologous С is apparently not required in all skin grafting 
systems in mice Winn et al [4, S] could destroy rat skin 
grafted onto mice by injection of mouse anti-rat serum or by 
rat alloantiserum without exogenous С However, m none of 
our allogeneic skin graft experiments was MC sufficiently 
activated, since injections of alloantibodies alone never in­
duced graft destruction [6] This is in keeping with the very 
low activity of MC in m vitro lymphocytotoxicity tests with 
mouse alloantibodies [7] 
The donor recipient combination (BIO D2 ->C57BL/6) used 
in the current study, consists of a complete H 2 complex dis­
parity in which we can induce acute antibody-mediated rejec­
tion (AAR) by the injection of RC, guinea pig complement 
(GpC), or human complement (HC) together with alloanti­
body [6] 
We have in this model tested various sera which were made 
deficient in isolated С factors, and sera from animals that 
were congenitally deficient in certain С factors We have used 
these С factor-deficient sera (R sera) to study the role of in­
dividual С components in our model of AAR Furthermore, 
this approach could delineate which components m the mouse 
endogenous С system are responsible for its low efficiency in 
cytotoxic tests and in AAR For this purpose we compared 
the m vivo results with the lymphocytotoxic activity of the 
various R sera in the presence or absence of normal mouse 
serum (NMS) 
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2 Materials and methods 
2 1 Animals 
Inbred BIO D2/new Sn (H-2d) mice were originally obtained 
from the Jackson Laboratory (Bar Harbor, ME) C57BL6/Rij 
(II 2 b ) mice were obtained from the Radiobiological Institute 
TNO (Rijswijk, NL) C4 deficient guinea pigs came from the 
National Institutes of Health, (Bethesda, MD) The C6 de­
ficient rabbits were provided by Dr Lachmann (Cambridge, 
G B ) 
2 2 Production of alloantiserum 
Alloanliserum was prepared by injecting female C57BL/6 
mice at weekly intervals, intrapenloneally (ι ρ ), with a sus­
pension of approximately 5 χ IO7 BIO D2 lymphoid cells 
in complete Freund's adjuvant After five injections, most 
animals developed ascites and could be tapped every 1 to 
2 weeks The ascitic fluid of several weeks was pooled and, 
before use all antisera were heated at 56 0 C during 45 mm 
and sterilized by passing them through a sterile 0 20 mji 
filter The cytotoxic titer of the ascitic fluid was the same 
as the titer in the serum of these mice Antisera were stored 
at - 20 0 C 
2 3 Anti-lymphocyte serum (ALS) 
This was prepared by a subcutaneous injection of 5 χ IO 7 -
8 χ IO7 C57BL/6 lymphoid cells (thymus and mesenterial 
lymph nodes) in complete Freund's adjuvant into a goat 
This priming dose was followed by weekly ι ν boosters of 
the same number of C57BL/6 lymphoid cells The animals 
were bled one week after the fourth immunization, the serum 
heated at 56 0 C for 45 mm, and absorbed once with C57BL/6 
red blood cells (5 vol of serum/1 vol of packed red blood 
cells) After absorption, this ALS was not toxic to the reci­
pients if injected ι ρ 
2 4 Complement 
Fresh or fresh frozen sera from New Zealand white rabbits, 
random bred SPF Albino guinea pigs, and from a human 
volunteer were used as sources of С Blood was obtained in 
rabbits and guinea pigs by cardiac puncture, in the human by 
venous puncture After clotting for 45 mm at room temper 
ature, and centnfugation the serum was divided into aliquots 
of 0 5 ml and, if not immediately used stored at - 3 0 0 C for 
maximally 3 weeks С was used only once after thawing Be 
fore use all sera were tested for toxicity m vitro (a 1 4 dilu­
tion should give less than 10 % cytolysis of В10 D2 lympho 
cytes), and in vivo by ι ν injection of 0 5 ml serum 
2 5 Reagents 
Veronal-buffered salme (GVB + + ), pH 7 35, containing 0 1 % 
gelatin 0 15 mM Ca',"r and 0 5 m M Mg+ +, relative salt concen­
tration (RSC) 0 147, was prepared accordmg to Mayer [8] 
The buffer was freshly prepared each day The rabbit anli-
sheep red blood cell antiserum and rabbit anti-human C9 
were commercially obtained from Behrmgwerke, Marburg, 
FRG Sheep red blood cells (SRBC) were drawn monthly 
from the same sheep, and collected in an equal volume of 
Alsever's solution Before use, SRBC were washed four times 
in ten volumes of G V B + + 
2 6 Production of R sera 
The Rl serum was prepared from pooled guinea pig serum 
by euglobulin precipitation (pH 7 5, RSC 0 04) accordmg 
to the method of Nelson [9] The precipitate was redissolved 
m a volume of GVB + + equal to the original serum volume 
The С1 free supernatant was brought back to a RSC of 0 15 
with NaCl after concentration to the original volume R4 
serum was obtained from C4-deficient guinea pigs R3 serum 
was prepared by incubation of guinea pig serum with boiled 
zymosan (Koch Light Laboratories, Colnbrook, Bucks , GB), 
15 mg/ml pooled guinea pig serum, for 60 min at 37 0 C 
After incubation, the zymosan was spun down in a refnger-
ated centrifuge The R6 serum was obtained from C6-de 
fluent rabbits R9 serum was prepared by absorption of C9 
from human serum by Sepharose coupled rabbit anti-human 
C9 antiserum The absorption procedure was performed at 
0 0C in the presence of 0 01 M fcDTA and was repeated until, 
after reconstitution with Ca + + and Mg't"t\ hemolytic activity 
was no longer detectable R9 serum was concentrated to the 
original volume at 0 0 C The R sera were sterilized by pas­
sage through a 0 20 π\μ filter AU R sera, when tested in a 
microhemolytic assay, were unable to lyse sensitized SRBC, 
while they were functionally active after reconstitution with 
the appropnate factor(s) 
2 7 Reconstitution of the R sera 
The reconstitution experiments were performed with functio­
nally pure GpC and HC factor preparations from Cordis Ltd 
(Miami, FL) In reconstitution experiments, Rl was recon­
stituted with the in G V B + + dissolved euglobulin precipitate, 
R4 with GpC4, R3 with guinea pig R4, R6 with GpCó and 
R9 with HC9 The R sera were serially diluted in GVB + + or 
Hanks' buffered salt solution (BSS) to which a constant amount 
of the deficient С factor had been added R l , R3 and R9 
serum and the reconstituted sera were always compared in 
the same test with the batch of С from which they were pre­
pared Th R4 serum was compared with pooled normal guinea 
pig serum, and the R6 serum with pooled normal rabbit serum 
In the lymphocytotoxicity tests an attempt was also made to 
reconstitute the R serum with NMS This was done in a two 
stage procedure to eliminate the anticomplementary activity 
that is often present in NMS No lymphocytotoxicity was 
found if NMS alone was used as a source of С 
2 S Serology 
A microhemolytic assay was performed on microliter plates 
Twenty five μ\ of the test sample were serially diluted in 
2 5 y l G V B + + Thereafter, 25 ді of SRBC (2 χ 10B/ml) sensi­
tized with anti SRBC antiserum (diluted 1 600) were added 
After mixing, the plates were incubated for 30 mm at 37 0 C 
After incubation, the plates were placed on ice to stop the 
reaction ¿nd centnfuged for 1 min in the cold The 5 0 % 
lysis point was taken as the titer R sera were also tested in 
a lymphocytotoxicity assay using the trypan blue exclusion 
test BIO D2 spleen cells were used as targets prepared free 
of red cells with Tm-NH^CI One hundred μΐ of cells (5 χ 105) 
in Hanks' BSS were incubated during 30 mm at 37 0 C with 
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equal volumes of CS7BL/6 anti В10 D2 antiserum (diluted 
1 16) and senal dilutions of whole C, R serum, reconstituted 
R serum, or С factors The titer was defined as the dilution 
giving 50 % cell lysis Tests were done in triplicate, and the 
following controls were performed (a) cell control 100 μ) 
cells in 200 μΐ Hanks' BSS, (b) antibody control 100 μ\ anti 
serum (diluted 1 16), 100 μΐ Hanks' BSS and 100 μΐ cells, 
(с) С control 100 μΐ undiluted C, R serum, reconstituted 
R serum, or pure С factor with 100 μΐ Hanks' BSS and 100 
μΐ cells In these controls cytolysis did not exceed 10 % 
2 9 Skin grafting technique 
Female BIO D2 tail skin was grafted onto the nght dorsal 
flank of female C57BL/6 recipients by a modification of the 
fitted graft technique The graft was fixed by Nobecutane 
spray Instead of plaster badage, we used band-aid to cover 
the graft The donor and recipient mice were between 6 and 
10 weeks old The band aid was removed on day 6 after 
transplantation and the fate of the grafts followed by daily 
macroscopic inspection Grafts were considered to be re­
jected when no viable epithelium remained Median survival 
time (MST) and the standard deviation (SD) were calculated 
by the method of Litchfield [ 10] The level of significance 
was calculated with Student's t-test 
2 10 Acute rejection studies 
The experiments were performed on well established grafts 
that showed no signs of rejection Survival of grafts was 
prolonged by nonspecific immunosuppression with ALS 
(0 25 ml ι ρ on days 0, 2 and 4 after grafting) from 9 3 + 1 1 
days to 19 0 ± 1 1 days (Table 1) Thus, an ongoing cellular 
rejection could not interfere with the antibody-mediated 
destruction induced at day 7 after grafting and completed 
within 2 4 - 7 2 h On day 7 the recipients received 0 5 ml 
C57BL/6 anti-B10 D2 antiserum and 0 5 ml C, R serum, 
С factor, or reconstituted R serum by an ι ν injection through 
the tail vein Control experiments were performed by inject­
ing antiserum, C, R serum and reconstituted R serum, alone, 
or the deficient С factor and alloantiserum AAR was defined 
as the complete necrosis of the skin graft 2 4 - 7 2 h after the 
iv injection 
3 Results 
3 1 Lymphocytotoxic activity of the R sera in vitro 
The titration curves of the va nous R sera are given in Fig I 
Rl serum The R l serum showed no cytotoxicity towards 
BIO D2 cells sensitized with alloantiserum After reconstitu­
tion with CI (100 μΐ of the redissolved euglobulin precipitate/ 
100 μΐ R l ) , the cytotoxic titer became 1 24 This is close to 
1 32, the original titer that was found with the batch of 
pooled guinea pig serum from which the R1 and С1 fractions 
were prepared The GpCl fraction itself had no cytotoxic 
activity If the cells were incubated with alloantiserum and 
NMS and washed, subsequent addition of GpC R l also pro­
duced a cytotoxicity of 1 24 Reversal of the procedure, ι e 
incubation of cells with alloantiserum and GpC-RI, followed 
by washing and addition of NMS, did not result in cytotoxi­
city This confirms earlier reports that the reconstituting 
factor in NMS is С1 [16], and is further supported by our 
finding that an euglobulin precipitate of NMS was as active 
in the reconstitution of GpC-RI as whole NMS 
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Figure 1 Lymphocytotoxic activity of the various R sera against 
BIO 02 spleen cells sensitized with C57BL/6 anü BIO D2 antiserum 
Each diagram represents the activity of normal C, R serum, reconsti 
tuted R serum, R serum in the presence of NMS, or the deficient factor 
102 
Complement factors in humoral rejection of skin grafts 
R4 serum Neither the R4 serum nor punfted GpC4 (12S0 
CH50 U/ml), or GpC-R3 showed cytotoxic activity against 
BIO D2 spleen cells Reconstitution of 100μ] GpC-R4 with 
100 μΐ GpC4 ( 1250 CHso U/ml) or with 100 μΐ GpC-R3 
restored cytotoxicity up to 1 24 It was not possible lo re­
constitute GpC-R4 with NMS 
R3 serum With the R3 serum no cytotoxicity was found, 
while addition of excessive amounts of GpC-R4 restored 
the cytotoxicity to the same titer as that of pooled GpC 
Reconstitution of the R3 serum with NMS was not possible 
R6 serum Neither the R6 serum norGpC6 (2500 CHSo U/ml) 
were able to lyse sensitized B\0 D2 spleen cells Retonbtitu-
tion of 100 μΐ Rt-R6 with 100 jul GpC6 ( 1250 CHso U/ml) 
restored the cytolytic activity up to 1 12, while normal RC 
in this (est system had a cytotoxic titer of I 32 Thus, we 
found a functional synergism between RC-R6 and ОрСб, and 
this is analogous to the findings of Rother et al who could 
reconstitute RC R6 with purified HC6 [11] Reconstitution 
with NMS was not possible 
R9 serum In the experiments with R9 serum the same pat­
tern was found as with GpC-Rl The R serum itself had no 
cytotoxic activity, neither had pure HC9 (5000 CHso U/ml) 
When 100 μ1€9 (5000 tH S o U% I) were added to 100 μΐ R9, 
the cytotoxicity was restored up to a titer of I 12, while nor 
mal HC had a titer of 1 16 NMS was also able to restore the 
cytolytic activity of human R9 up to a titer of 1 12, if NMS 
was added after incubation of sensitized target cells with the 
R serum 
3.2 Ability of R sera to induce AAR 
By the administration of 0 S ml RC, GpC, or HC together 
with 0 5 ml alloanlisemm, AAR could be induced within 48 h, 
while alloantiserum alone, or the various С species alone gave 
negative results The MST of the control groups did not dif­
fer significantly from the ALS-treated group (Table 1) The 
in vivo results with the different R sera are summarized in Ta­
ble 2 It was possible to induce AAR with GpC-R 1, while in­
jection of R serum without alloantiserum was ineffective A 
similar pattern was observed with the HC-R9 serum 
Table 1. Occuircnce of AAR and MST of BIO D2 skin giafu on 
C57BL/6 recipients m va no us control groups 
No of 
¡murali 
150 
13-1) 
10 
16 
10 
10 
β 
10 
11 
C57BL/6 anti-BIO D2 
antlierum1) 
-
+ 
+ 
+ 
+ 
Complé-
ment·) 
-
-
RC 
RC 
GpC 
GpC 
HC 
HC 
AARb) 
-
+ 
+ 
+ 
MSTiSD 
9 3 i 1 1 
1 9 0 i 1 1 
23.0 1 1 1 
18 6 1 1.1 
2 1 5 1 1 1 
19 4 t 1.1 
a) 0 5 ml ι ν on day 7 after grafting 
b) Defined as complete necrosis of the skin graft 24-72 h after 1 ν 
injection 
c) Untreated animals 
d) Recipients received 0 25 ml ALS ι ρ on days 0, 2 and 4 after graft 
ing 
Table 2 Induction of AAR by 1 ν injection of the various R sera and 
alloantiserum on day 7 after grafting 
R serum AARa) 
R serum and R senim Reconstituted Reconstituted 
alloandbody only R serum and R serum only 
alloantibody 
GpCRl 7/ 7b) 0/8 
HC-R9 6/ 6 0/6 
GpC-R4 0/12 11/11 0/8 
GpC-R3 Q/ll Π/11 0/8 
RC-R6 0/11 10/10 0/8 
a) Defined as complete necrosis of the graft 24 72 h aften ν injec­
tion 
b) Number ot animals that showed complete necrosis of Mie graft/ 
number animal* tested 
Administration of GpC R4 with alloantiserum did not induce 
AAR Addition of pure GpC4 to the R4 serum before the in­
jection did not reconstitute the destructive capacity of the 
R serum Even doses as high as 5000 CH50 U were ineffective 
This was somewhat surprising since m vitro, the lymphocyto-
toxicity of the R4 scrum was completely restored by C4 A 
possible explanation might be that after the injection of the 
reconstituted R serum, GpC4 is rapidly inactivated in the 
mouse circulation [12] However, AAR was obtained with 
R4 serum that had been reconstituted with guinea pig R3 
serum Injection of this mixture without alloantiserum did 
not lead to AAR 
The R3 serum did noi induce AAR if injected together with 
alloantiserum Active C3 is not available since its isolation 
leads to inactivation Thus, in this instance wc were unable 
to reconstitute the defect with the appropriate factor How 
ever, in the experiments with R4 serum it had already been 
shown that combination of R3 and R4 resulted η compie 
mentation and led to induction of AAR 
Induction of AAR with R6 serum and alloantiserum was also 
impossible Reconstitution of 0 5 ml R6 serum with an equal 
amount of guinea pig C6 ( 1250 CH50 U/ml) lead to destruc­
tion of the graft if the mixture was injected with alloantiserum 
In the control experiments, injections of only C6 with allo­
antibody or reconstituted R serum alone did not result in 
rejection 
4 Discussion 
Our results show that for the induction of AAR in our model 
not all heterologous С factors have to be administered GpC Rl 
and HC R9 were as effective as normal GpC and HC. showing 
that the mouse can reconstitute the defect On the other 
hand, the limiting effect of MC does not he at a single point 
in the С sequence since three sera deficient in different С 
components were only able to induce rejection after rcconsti 
tution with the appropriate factor 
In all but one experiment (R4 reconstituted with C4) we 
found in R sera a close correlation between С activity m intro 
and tn vivo AAR occurred only if the R serum had cytotoxic 
activity in vitro after reconstitution with the deficient factor, 
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or with NMS This suggests that the С system is activated 
similarly in vivo and in vitro From the expenments with 
GpC*R4 it can be concluded that m vivo С activation in our 
model is initiated via the classical pathway, as it is ш іл vitro 
cytotoxicity of cells sensitized with antibody If alternative 
pathway activation alone were sufficient to induce AAR, then 
administration of the R4 serum should have induced rejec­
tion, since activation of the alternative pathway is normal 
in this serum [13] At least three murine С factors, C4, C3 
and C6, are relatively inefficient in this system since NMS 
could not reconstitute these R sera neither m virro nor m 
vivo With regard to C4 and C3 these findings are in accord 
with those of Rice, who in a hemolytic system found that 
CpC-R4 and R3 were not reconstituted by NMS [14] Mouse 
CI, on the other hand, seems not to be at fault NMS and 
also its euglobuhn precipitate, reconstituted the GpC-RI 
serum in vitro This complémentation confirms previous find-
ings of other investigators who obtained similar results in a 
hemolytic system with sensitized SRBC [ 1 4 - 1 6 ] Since the 
Rl serum tould induce graft rejection without reconstitution 
with exogenous С1, we must conclude that also in vivo the 
mouse effectively provided the deficient CI factor 
It has been suggested by Winn [4] that for antibody-mediated 
graft destruction, activation of the complete С pathway is 
unnecessary He assumed that the generation of chemotactic 
С components is sufficient for the destruction of the graft 
This was based on expenments with CS-deficient mice that 
rejected rat xenografts after the administration of mouse 
anti-rat serum These mice are completely deficient in CS, 
and thus activation beyond this component is impossible 
Care was taken to prevent administration of exogenous С 
components with the anti-rat serum On the basis of his 
findings, we expected that our R6 serum would also induce 
rejection, but this was clearly not the case This cannot be 
the result of deficient chemotactic properties of the R6 serum, 
Since it has been shown to generate normal Chemotaxis [ Π ­
Ι 9] and lacks only lytic activity We have preliminary un­
published data from histological studies that after administra­
tion of R6 serum, the granulocyte infiUration in the graft is 
as abundant as after the injection of whole RC Despite this, 
destruction did not occur with R6 We therefore assume that 
in our model complete С activation with generation of not 
only chemotactic but also membranolytic activity is necessary 
to induce AAR 
We think that the only possible explanation for the induction 
of AAR by R9 serum is that the mouse endogenous C9 is 
efficient enough to complement exogenous R9-serum especi­
ally after this is what happened in the in virro test It is highly 
unlikely that graft destruction occurred without activation of 
C9, but this possibility could not be formally excluded through 
lack of a negative control in the m vivo experiments This 
would require a mouse completely deficient in C9, and in such 
an animal the R9 serum would fail to induce AAR 
We may thus conclude that for the induction.of AAR, the 
complete С pathway has to become activated via the classical 
pathway, and that generation of chemotactic С components 
alone is not sufficient Our study gives some indications for a 
useful approach to influence the occurrence of antibody-medi­
ated graft destrULtion by manipulation of the С system If it 
becomes possible to inhibit С activity in vivo it seems wise to 
concentrate on the early factors such as С1 or C4 because 
deficiency of these factors might lead to inhibition of humor 
ally mediated rejection Such an approach would leave the 
alternative pathway fully intact so that the C-dependent de­
fense mechanisms against bacterial infections remain unaltered 
This would be of great ad\antage in clinical transplantation 
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Under appropriate conditions the haemolytic activity of mouse complement can be 
measured in a 5ICr release assay. Modifications that increase the sensitivity are the follow-
ing: (a) mouse 7 S anti-SRBC antibodies as amboceptor; (b) low amount of target cells; 
(c) ionic strength of 0.13 M NaCl in the test medium; (d) incubation temperature of 
30oC; (e) incubation time of 90 min; (f) total reaction volume of 1 ml. 
INTRODUCTION 
In tests that are generally used to measure the haemolytic activity of 
human and guinea pig complement, mouse serum seems to lack complement 
activity (Brown, 1943; Rice and Crowson, 1950). In 1952 McGhee reported 
that in a system with a very low number of sensitized sheep red blood cells 
(SRBC) one CH50 U/ml could be detected in some mouse sera, while other 
sera from mice of the same strain were still unable to induce haemolysis. 
Several authors claimed that some of the then known complement factors 
(CI, C4, C2, C3) were absent from the mouse complement system, and that, 
therefore, no haemolytic activity could be demonstrated (Ritz, 1911; 
Brown, 1943; Rice and Crowson, 1950; Muschel and Muto, 1956). In 1961, 
however, Borsos and Cooper found, by using cellular intermediates, that all 
these factors were present in at least the mouse strain they tested. Later on it 
became evident that some inbred strains lack haemolytic activity due to lack 
of C5 (Nilsson and Müller-Eberhard, 1967). Although this C5 deficiency 
could explain the inability to demonstrate haemolytic activity of mouse 
complement in these strains it did not explain why in other strains that were 
not C5 deficient, С activity was so difficult to measure. 
In 1962 Rosenberg and Tachibana described an assay for the measurement 
of haemolytic activity of mouse complement, but its sensitivity was rather 
low. In 1975 Stolfi et al. mentioned a method that used spectrophotometric 
determination of the haemoglobin release but details of the method have not 
been published. Mouse sera are always spontaneously, and sometimes 
* This study was partly supported by grants from the Netherlands Foundation for Medi 
cal Research FUNGO and from the Netherlands Kidney Foundation. 
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strongly, haemolysed. This interferes with the measurement of haemoglobin 
release due to complement activity, and makes the above mentioned 
approach less attractive. To overcome this problem we have developed an 
assay that makes use of slCr-labelled sheep red blood cells. This technique 
has a greater sensitivity than the determination of haemoglobin release 
(Weinrach et al., 1958). We describe here the optimum conditions for this 
51Cr-release test. We have also studied how the haemolytic activity of mouse 
complement is influenced by the use of different amboceptors and by 
variation of the reaction conditions. 
MATERIALS AND METHODS 
Mice 
Inbred lines of B10.D2/old Sn and A/HeJ mice were originally obtained 
from the Jackson Laboratory (Bar Harbor, Maine, U.S.A.). C57BL6/Rij mice 
were obtained from the Radiobiological Institute TNO (Rijswijk, The Nether-
lands). DBA/2 and A/J mice were brought from Zentral Institut für Versuchs-
tierzucht, Hanover, G.F.R. In our animal laboratory these mouse strains were 
maintained by continuous brother sister matings. (C57BL6/Rij X A/HeJ)Fi 
(=B6AF1) hybrids were raised in the laboratory. 
Production of mouse amboceptor 
Mouse amboceptor was prepared in C57BL6, A/J and B6AF1 mice in two 
different ways. The first method consisted of weekly intraperitoneal injec-
tions of 4 X 107 SRBC in 0.1 ml 0.9% saline. One week after the 5th immuni-
zation the mice were bled from the retro-orbital venous plexus. After clot-
ting for 45 min at room temperature, the separated serum was heated for 
45 min at 56°C to destroy complement activity. The sera were stored at 
—30oC. For the production of larger amounts of amboceptor in the same 
strains we gave weekly intraperitoneal injections of 4 X 107 SRBC in 0.1 ml 
0.9% saline mixed with 0.1 ml complete Freund's adjuvant. After 5 injec-
tions most animals developed ascites, which was tapped every week. The 
product of several weeks was pooled. Before use, the ascites fluid was heated 
at 56°C for 45 min, and sterilized by passing through a sterile 0.20 nm filter. 
The haemolytic titer of the ascites fluid was the same as that of the serum of 
these mice. The sera were divided into 1 ml aliquots and stored at —30oC. 
Complement 
All experiments were performed with pooled mouse sera. The mice were 
bled from the retro-orbital venous plexus. After clotting for exactly 45 min 
at room temperature, the serum was collected by centrifugation at 40C, and 
stored in liquid nitrogen. Fresh serum from special pathogen free random 
bred Albino guinea pigs served as a source of guinea pig complement. 
Reagents 
If not otherwise stated all titrations were performed in dextrose gelatin-
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veronal buffer (DGVB2+) containing 0.00015 M Ca2+ and 0.0005 M Mg2+ 
(pH 7.35), ionic strength of 0.13 M NaCl, and prepared according to Rapp 
and Borsos (1970). The ionic strength was determined by measuring specific 
conductance at 20oC. The buffer was freshly prepared each day. Rabbit 
amboceptor was obtained commercially from Behring Werke. 
SRBC were obtained aseptically from the same sheep each month. Blood 
was collected in an equal amount of Alsever's solution, and stored at 40C. 
Before labelling with s l Cr (Sodium Chromate, 50—400 mCi/mg/Cr, Radio­
chemical Center, Amersham, U.K.) the SRBC were washed four times with 
DVGB2+. One millilitre SRBC (containing 8 X 107 cells) was labelled with 
6 μΟ 51Cr, by incubation during 60 min at 37°C. This resulted in 90% 
binding of the radioactivity (Ebaugh et al., 1953). With this dose of sodium 
Chromate no injury to erythrocytes occurs (Necheles et al., 1953). After 
incubation the labelled SRBC were washed three times with 10 volumes 
of DGVB2+, and the pellet resuspended in the original volume. To prepare 
sensitized cells (EA), an equal volume of an appropriate dilution of 
amboceptor in DGVB2+ was slowly pipetted into the labelled SRBC suspen­
sion with continuous mixing. The EA cell suspension was then incubated 
for 10 min at 370C with frequent mixing. The spontaneous release of 5 1Cr 
from this cell suspension during the first 48 h was 2—4% of the total activity 
bound. 
Separation of mouse amboceptor in IgG-IgM antibodies 
This was performed with isokinetic sucrose gradients, prepared by addi­
tion of 33% (w/w) sucrose in phosphate buffered saline (PBS) to 12 ml 5% 
(w/w) sucrose in PBS in a mixing chamber at constant volume (Noll, 1973). 
Test serum (0.5 ml) was layered on top of a 12 ml gradient and centrifuged 
in a SW 41 rotor (IEC) at 35,000 rev./min for 16 hours at 40C. The gradient 
was sampled from the bottom; 0.8 ml fractions were collected and each 
fraction was tested for agglutinating and haemolytic activity. 
Serologic tests 
Basic outline of the haemolytic assay of mouse complement. The tests 
were performed in sterile plastic tubes. The mouse serum to be tested was 
diluted 1 : 10 in DGVB2+ and 10—800 μΐ was put in tubes containing varying 
amounts of DGVB2+ to produce dilutions with a final volume of 800 μΐ. The 
dilutions were chosen such that at least 4 dilutions gave partial lysis. After 
adding 200 μΐ of 51Cr-labelled EA suspension (4 Χ 107 cells/ml) the tubes 
were incubated in a waterbath at different temperatures, and for different 
incubation periods. After incubation the tubes were placed on ice, and 2 ml 
of ice-cold DGVB2+ were added to quench the reaction. The tubes were then 
centrifuged for 5 min at 3,000 rev./min at 4°C. From each tube 2 ml super­
natant was collected to measure the released s l C r activity. Each test included 
the following controls (in triplicate): (a) 200 μΐ of EA suspension in 800 μΐ 
DGVB2+ to determine spontaneous s l C r release; (b) 200 μΐ of EA suspension 
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lysed in 800 μΐ water to measure 100% lysis; (c) 200 μΐ of SRBC incubated 
with the highest amount of mouse serum used in that test, to exclude the 
presence of naturally existing mouse antibodies against SRBC. The released 
s l Cr activity in each tube was measured for 10 min in a gamma-ray well type 
scintillation counter (MS 588, Beard Atomic). The fraction of SRBC lysed 
in each dilution was calculated according to the formula: 
cpm test serum—cpm control 
cpm complete lysis—cpm control 
The data were plotted according to the logarithmic transformation of the 
Von Krogh equation to determine the CH50 titer per ml of undiluted mouse 
serum. 
Antibody titrations of different amboceptor species. We studied the 
influence of the amboceptor species by comparing rabbit amboceptor in a 
limited complement system with different mouse amboceptors (A/J, 
C57BL6 and B6AF1). One hundred microliters of amboceptor were diluted 
in 2-fold steps in 100 μΐ DGVB2 +. To these serial dilutions 100 μΐ of 51Cr-
labelled SRBC (8 X 107/ml) were added. After incubation for 10 min at 
370C, 6μ1 of MC (C57BL6 male mouse serum) and 794 μΐ DGVB2+ were 
added, and incubated for 90 min at 30oC. Percentage lysis (fraction X100) 
was calculated for each amboceptor dilution. 
Antibody titrations of different anti-SRBC antibody classes. After ultra-
centrifugation of the different mouse amboceptors on a sucrose gradient 
25 μΐ of each collected fraction was diluted in 2-fold steps in 25 μΐ DGVB2* 
in microtiter plates. To test the agglutinating activity 25 μΐ of SRBC (108/ 
ml) were added, and after mixing, the plates were incubated for 30 min 
at 370C. To test the haemolytic activity 25 μΐ SRBC (108/ml) were added to 
the amboceptor dilutions, incubated for 10 min at 370C, and thereafter 
25 μΐ guinea pig serum or 25 μΐ B10.D2 male serum were added. After 
mixing, the plates with GPC were incubated for 30 min at 37CC, and those 
with MC for 90 min at 30CC. The plates were centrifuged for 1 min at 
1000 rev./min at 40C, and read macroscopically. The titer was defined as the 
last dilution that gave complete haemagglutination or lysis. All tests were 
performed in duplicate. 
RESULTS 
Amboceptor species and class of anti-SRBC antibody 
As can be seen in Fig. 1, mouse and rabbit amboceptor give comparable 
haemolysis. Both antisera exert strong anticomplementary effects, and 
maximal lysis requires relatively high concentrations of antibodies (dilution 
of 1/8 to 164). Mouse amboceptors had the advantage of giving less haemag­
glutination during sensitization of the SRBC than rabbit amboceptor. A 
difference in activity was observed between the three mouse amboceptors. 
With C57BL6 amboceptor maximal lysis occurred at a lower dilution than 
110 
·/. cell lysis 
ЮОл 
- ι 1 1 1 1 г 
16 64 256 1024 256 1024 
(amboceptor dilution)" 
Fig. 1. Titration of three mouse and one rabbit amboceptor in a limited complement 
system (measured with 6 μΐ C57BL6 male MC). Each point represents the mean value 
of 4 different tests, the vertical bars give the S.E. M. 
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Fig. 2. Haemagglutinin and haemolytic titers of A/J, B6AF1 and C57BL6 amboceptor 
fractions, collected after separation on an isokinetic sucrose gradient. Haemolysis was 
measured with GPC and MC. 
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with B6AF1 and A/J, and the maximal lysis reached was also lower. Silver 
et al. (1972a; 1972b) reported that the antibody response to SRBC in 
C57BL6 mice was different from that in mice of the A strain'. In C57BL6 
they found a predominantly 2-ME sensitive (IgM) response, while in A mice 
the antibodies formed were 2-ME resistant (IgG). Furthermore, Winn (1965) 
observed that mouse complement (MC) was better activated by IgG anti-
SRBC antibodies, while by contrast, GPC was better activated by IgM anti-
SRBC antibodies. To study whether the higher haemolytic activity of A/J 
amboceptor as compared to C57BL6 amboceptor in our system was due to 
the class of antibody present in these amboceptors, we separated IgG and 
IgM antibodies of A/J, C57BL6 and B6AF1 amboceptor with isokinetic 
sucrose gradients. The results are shown in Fig. 2. In the haemagglutination 
test the A/J amboceptor contains more 7 S anti-SRBC antibodies, while 
C57BL6 amboceptor contains more 19 S antibodies. The values for B6AF1 
amboceptor are intermediate between those of the other two strans. A 
comparable pattern was found in the haemolytic test with MC, where in 
A/J and B6AF1 serum only 7 S antibodies were haemolytic, while in the 
C57BL6 serum lysis by 19 S was predominant. It is also clear from this 
figure that MC is better activated by IgG than by IgM antibodies, since 
the haemolytic titer of 7 S A/J antibodies with MC was 1 : 32, while with 
19 S C57BL6 antibodies, of comparable haemagglutinating activity, the 
titer was only 1 : 2. For GPC a better activation by 19 S anti-SRBC was 
found, which is in agreement with findings of other investigators (Winn, 
1965; Borsos and Rapp, 1965; Ishizaka et al., 1968). The results thus suggest 
that for the optimal determination of MC amboceptor containing 7 S anti-
bodies (e.g., A/J anti-SRBC serum) should be preferentially used to sensitize 
SRBC. 
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Fig. 3. Haemolytic activity of B6AF1 male MC from a single batch measured at different 
incubation temperatures. Each point represents the mean of 4 different tests; the vertical 
bars are the S.E.M. 
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Fig. 4. Haemolytic activity of B6AF1 male MC from a single batch at different ionic 
strengths. Each point represents the mean value of 4 different tests; the vertical bars are 
the S.E.M. 
Incubation temperature 
It has been shown for several complement species that a lower incubation 
temperature than 370C gives better haemolysis (Leon, 1956; Borsos et al., 
1961; Colten et al., 1967; Cooper and Müller-Eberhard, 1968; Cunniff and 
Stollar, 1968; Sakamoto, 1975). To find out which incubation temperature 
was optimal for mouse complement we performed a haemolytic titration of 
the same batch of B6AF1 MC m quadruplicate at 15°C, 2 2 ° ^ 30oC and 
370C (Fig. 3). The figure shows that for MC an incubation temperature of 
30oC is optimal. 
Ionic strength 
Lepow et al., (1956) stated that a lower ionic strength of the test medium 
resulted in a higher haemolytic activity of human complement (HC). Later 
many reports confirmed these findings for GPC and HC (Becker and Wirtz, 
1959; Rapp and Borsos, 1963; Inoue and Nelson, 1965; 1966; Gölten et al., 
1968; Shin et al., 1971; Segerling and Muller, 1976). To find out whether 
this also holds true for MC we measured the CH50 titer of the same batch 
of B6AF1 MC (in quadruplicate) at different ionic strengths. The buffers 
were prepared by adding appropriate amounts of veronal buffered dextrose 
5% (with 0.1% gelatine, 0.0005 M Mg2+, 0.00015 M Ca2+) to GVB2+. We 
found an optimum at 0.13 M NaCl (Fig. 4). 
Incubation time 
The time necessary to obtain maximal lysis was measured in the presence 
of one CH50 unit of MC (9 μΐ B6AF1 male serum) at 300C with 8 X 106 
sensitized SRBC, total reaction volume 1 ml. After 90 min of incubation no 
further increase in haemolysis wis found (Fig. 5). In the presence of a lower 
amount of MC (7 μΐ B6AF1 serum) the time necessary to obtain maximal 
lysis increased to 120 min. 
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Fig. 5. Percentage lysis of SRBC measured in a limited complement system at increasing 
incubation times. (I) Measured with 9 μΐ B6AF1 male mice MC, (II) with 7 jul B6AF1 
MC. Each point represents the mean percentage lysis of four different tests. The S.E.M. 
for each point was < 1%. 
Reaction volume 
By decreasing the total reaction volume haemolytic tests become more 
sensitive (Mayer et al., 1946), and less serum is necessary to determine the 
CH50 titer. This is of special advantage in measuring haemolytic comple­
ment activity of mouse serum, because in most instances there is only a 
small volume of serum available. The same batch of mouse complement 
measured in total reaction volumes of 1 and 3 ml respectively gave a CH50 
titer of 148.6 ± 2.0 and 69.9 ± 1.5 U/ml (means ± S.E.M. of 4 determina­
tions). 
Number of sensitized SRBC 
To determine the influence of the number of sensitized SRBC on the 
CH50 titer ( U/ml) 
300 
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50 
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sensitized SRBC 
Fig. 6. Relation between CH50 titer (U/ml) of male C57BL6 MC and number of labelled 
SRBC added. Each point gives the mean titer of four measurements, the vertical bars are 
the S.E.M. 
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TABLE 1 
COMPLEMENT LEVELS IN DIFFERENT INBRED MOUSE STRAINS * 
B10.Br 
C57BL6 
B6AF1 
A/HeJ 
DBA/2 
Ss-low 
Ss-high 
Ss-high X C5 deficient 
C5-deficient 
CS-deficient 
48.1 ± 4.1 
167.5 ±10 .7 
77.3 ± 4.1 
0 
0 
Strain Complement status CH50 titer »* ± SEM U/ml 
Male Female 
34.9 ±4 .9 
63.8 ± 3.9 
45.9 ± 1.7 
0 
0 
* All mice were 6 weeks old. 
** Each value is the mean of determinations in 6 mice. 
CH50 titer we measured the CH50 titer of the same batch of C57BL6 MC 
to which different numbers of sensitized SRBC were added, under otherwise 
similar test conditions. We found a linear relationship between the CH50 
titer and the number of SRBC if the results were plotted semi-logarithmi-
cally (Fig. 6). It should be noted that although sensitivity is highest with 106 
SRBC the reproducibility is less at this concentration. 
Reproducibility of the test 
The intra-assay precision, determined by the coefficient of variation of 
25 measurements of sera with complement levels ranging from 4—300 
CH50 U/ml varied from 0.3—5.1%. Inter-assay variation with the same 
sera was 3.1—7.1%. 
Complement levels in different inbred mouse strains 
Since the investigations of Demant et al. (1973) it has become evident 
that a correlation exists between complement activity and H-2 haplotype, 
especially with the Ss-region allotype. To demonstrate the applicability of 
the method we measured complement levels in Ss-high and Ss-low mice. 
Furthermore we measured complement activity in some C5 deficient mice, 
and in a hybrid of a C5 positive and C5 negative parental strain (Table 1). 
In agreement with Nilsson and Müller-Eberhard (1967) the results also 
show a difference in complement level between male and female mice. 
DISCUSSION 
Mouse complement is very difficult to measure in standard haemolytic 
assays and test conditions have therefore to be modified. An important 
improvement in the system is the replacement of measurement of haemo-
globin release by that of s lCr release. The first advantage of this is that the 
number of target cells may be decreased which leads to higher sensitivity. 
For example, the CH50 titer of C57BL6 mice measured with our method 
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was 10 times higher than in the method of Rosenberg and Tachibana (1962). 
Second, the error introduced by the fact that many mouse sera are haemo-
lysed is eliminated. A third advantage is that in spite of the increased sensi-
tivity of the assay, its coefficient of variation is very small. 
The results of antibody titrations with amboceptors from different mouse 
strains stress the importance of the antibody class used. Mouse complement 
is much more readily activated by IgG than by IgM. We found that C57BL6 
mice make predominantly IgM antibodies, while A/J mice produce mostly 
IgG after multiple immunization with SRBC. 
Our findings confirm those of Silver et al. (1972a; 1972b), although there 
are quantitative differences. These might be accounted for by differences in 
technique since we used sucrose-gradient centrifugation instead of 2-
mercapto-ethanol sensitivity to distinguish the two classes. The differential 
activity of 7 S and 19 S amboceptors with regard to the activation of mouse 
complement has practical implications because a sample of the same batch 
of MC tested with SRBC sensitized with A/J amboceptor gave a CH50 titer 
approximately 50% higher than with C57BL6 amboceptor. 
On the basis of our findings we may summarize practical guidelines for 
the use of the assay as follows: (a) number of sensitized SRBC: 8 X 106 cells; 
(b) amboceptor class: IgG; (c) incubation temperature: 30oC; (d) ionic 
strength: 0.13 M NaCl; (e) incubation time: 90 min; (f) reaction volume: 
1 ml. With this test substantial differences in complement activity between 
different mouse strains were found. The method offers an opportunity to 
measure sensitively complement levels in an animal experimental system 
widely used in immunological research. 
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INTRODUCTION 
Two experimental systems have been described in which skin 
grafts carried by mice can be acutely destroyed by the administra-
tion of antisera directed against the graft antigens (1,2). One 
of these consisted of allogeneic skin grafted onto mice, that 
were treated with anti mouse lymphocyte serum to suppress cellular 
immunity (2). On day 7 after transplantation, when the grafts 
showed no signs of rejection the recipients received an injection 
of alloantiserum along with fresh rabbit serum as a source of 
complement. Acute graft destruction occurred within 24-48 h. 
Administration of exogenous complement was essential, since in-
jection of antiserum alone did not destroy the grafts. This system 
enabled us to study the mechanism of humorally mediated graft 
destruction. Histologically, the grafts showed the characteristics 
of an Arthus reaction with dense infiltration of polymorphonuclear 
leukocytes (PMN) as early as 30 minutes after the antiserum in-
jection, followed by extravasation of erythrocytes and necrosis. 
It was subsequently shown that activation of the complete comple-
ment pathway was necessary for destruction to occur (3). 
Our experimental system was based on an earlier study, in 
which rat skin grafted onto immunosuppressed mice was destroyed 
by injection of anti rat serum (1). Histological changes in these 
grafts were also of the Arthus type. Apparently the mouse endoge-
nous complement was activated in this xenogeneic system of wide 
antigenic disparity, since administration of exogenous complement 
was not necessary to cause destruction. Further work of Winn in 
this system showed that acute destruction could be induced in C5 
deficient mice, while on the other hand, C3 depletion by cobra 
venom factor, or PMN depletion with anti granulocyte serum, in-
hibited the graft destruction (4). This suggested that activation 
of C3 with consequent PMN attraction sufficed to induce tissue 
damage in this xenogeneic graft model. Complement mediated cyto-
lysis of the grafts by the late acting complement components did 
probably contribute to the damage because the rejection in mice 
with a normal complement status had a more violent course, but 
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it played no essential role. Although these experiments show that 
complement is a very important factor, it was not completely ex-
cluded that graft destruction by antibody in this system also 
occurred via complement independent mechanisms. The finding that, 
in C3 depleted mice, grafts that were not rejected all showed 
signs of inflammation might serve as an argument for such a com-
plement independent destruction. 
We have used a comparable xenogeneic system, to study antibody 
mediated rejection and now present evidence that another, comple-
ment independent, pathway of graft damage exists. This complement 
dependency of graft rejection in this system was studied by using 
complement deficient or complement depleted recipients, or alter-
natively, by injecting non-complement fixing antibodies. Histo-
logic studies were done in addition to macroscopic inspection of 
the grafts, to obtain information on the mediators that were res-
ponsible for the destruction. 
MATERIALS AND METHODS 
Animals. Inbred C57BL6/RÌJ mice were originally obtained from the 
Radiobiological Institute TNO, Rijswijk (The Netherlands), and 
DBA/2 (C5 deficient) mice from the N.I.H. Bethesda (Maryland, 
U.S.A.). Inbred PVG/c rats came originally from the Institute of 
Psychiatry, Bethlem Royal Hospital, Beckingham (Kent, U.K.). 
In our laboratory these strains were kept by continuous brother-
sister matings. 
Transplantation procedure. Male PVG/c tail skin was grafted onto 
the flank of male C5 7BL6 or DBA/2 recipients by a modified fitted 
graft technique (3). The fate of the grafts was followed by daily 
macroscopic examination. Grafts were considered to be rejected 
when no viable epithelium remained. Median survival times (MST) 
and standard deviations (SD) were calculated according to the 
method of Litchfield (5). To postpone cellular rejection of the 
grafts all recipients were treated with rabbit anti mouse lympho-
cyte serum (RAMLS) or the Ig fraction thereof RAMLG) on days -2, 
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-1, О, 2 and 4 after grafting in a dose of 0.25 ml i.p. This 
immunosuppressive regimen prolonged the MST of PVG/c grafts to 
23.0 + 1.2 days in C57BL6 recipients and to 24.5 + 1.3 days in 
DBA/2 mice. 
Acute reiection studies. On day 7 after grafting, when all grafts 
were well healed m and showed no signs of rejection, the recip­
ients received mouse anti rat serum (MARS) or its Ig fraction 
(MARG) via an intravenous (i.V.) injection in the tail vein. In 
mice that are not complement deficient this results in a rapid 
and violent graft destruction. In this study we define this acute 
antibody mediated rejection (AAR) as the complete necrosis of the 
graft within 24-72 h after the i.v. injection of anti rat serum. 
Complement depletion. Attempts to induce complement depletion in 
vivo were first made with four agents that are known to have anti­
complementary effects in vitro. These agents were: suramin 
(Germanin ) provided by Bayer, Mijdrecht, the Netherlands; 
flufenamic acid (Arlef ) provided by Parke-Davis, Mijdrecht, the 
Netherlands; pentamidine (Lomidine ) provided by Specia, Amstelveen, 
the Netherlands, and carrageenin commercially obtained from Sigma 
St. Louis, U.S.A. In vivo dosages were as high as possible, but 
such that there were no toxic effects to the recipients. In a 
second series of experiments cobra venom factor (CoVF), 100 U/ml 
(Cordis Ltd, Miami, U.S.A.) was used as an anticomplementary agent. 
Antisera. RAMLS was prepared according to the method of Gray et 
al (6). MARS was prepared in C57BL6 mice by weekly i.p. injections 
of 5 χ 10 PVG/c lymphoid cells suspended m complete Freund's 
adjuvant. After five injections the animals developed ascites, 
that was tapped weekly. The lymphocytotoxic titer of the ascites 
fluid was the same as the titer in the serum of these mice. The 
antisera, if not used for preparation of Ig fractions, were pooled 
and heated at 56 С for 45 min to destroy complement activity, and 
sterilized by passage through a sterile 20 mp filter (Scheicher 
and Schüll, Dassel, West Germany). 
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P r e p a r a t i o n of Ig f r a c t i o n s from a n t i s e r a . From RAMLS and MARS 
Ig f r a c t i o n s (RAMLG and MARG) were p r e p a r e d i n o r d e r t o o b t a i n 
p r e p a r a t i o n s f ree of complement f a c t o r s . The Ig f r a c t i o n s were 
p r e c i p i t a t e d in 50% s a t u r a t e d ammoniurnsulphate, and s u b s e q u e n t l y 
d i a l y s e d a g a i n s t phospha te b u f f e r e d s a l i n e (PBS). The d i a l y s a t e 
was p u t on a Sepharose 4B-CL coupled P r o t e i n A column (Pharmacia , 
Uppsa la , Sweden). A f t e r s u f f i c i e n t washing wi th PBS, immuno-
g l o b u l i n s were e l u t e d from t h i s column w i t h 0.05 M s o d i u m c i t r a t e 
b u f f e r pH 2 . 8 , c o n t a i n i n g 1 M NaCl. The e l u a t e was immedia te ly 
n e u t r a l i z e d and d i a l y s e d a g a i n s t PBS. The MARG-dialysate was 
c o n c e n t r a t e d t o a volume t h a t had the same c y t o t o x i c i t y i n v i t r o 
towards PVG/c lymphoid c e l l s as the MARS p r e p a r a t i o n from which 
i t o r i g i n a t e d . RAMLG was c o n c e n t r a t e d and used in dosages t h a t 
gave s i m i l a r p r o l o n g a t i o n of g r a f t s u r v i v a l as the o r i g i n a l 
RAMLS p o o l . 
P r e p a r a t i o n of IgGl and IgG2 s u b c l a s s an t ibody from MARG. Non 
complement f i x i n g (IgGl) and complement f i x i n g (IgG2) a n t i b o d i e s 
were p r e p a r e d from MARG by a f f i n i t y chromatography acco rd ing t o 
an e a r l i e r d e s c r i b e d method ( 7 ) . Contamina t ing immunoglobulins 
were removed from the IgGl and IgG2 p r e p a r a t i o n s by r e p e a t e d runs 
on Sepharose columns coa ted wi th a p p r o p r i a t e immunoglobulin a n t i -
b o d i e s . The p u r i t y of t he f i n a l p r e p a r a t i o n s was t e s t e d by r a d i a l 
immunodiffusion. Contamina t ing IgA o r IgM could no t be demon-
s t r a t e d (lower l i m i t of d e t e c t i o n < 0.05%). The f i n a l IgGl p r e -
p a r a t i o n t h a t c o n t a i n e d 13,000 yg I g G l / m l , was con tamina ted wi th 
0.0 5% IgG2, and the IgG2 p r e p a r a t i o n (8,700 pg IgG2/ml) w i th 0.1% 
IgGl . 
Se ro logy . The measurement of h e m o l y t i c complement a c t i v i t y of 
t he mouse was performed wi th a C r - r e l e a s e assay t h a t has been 
d e s c r i b e d e l sewhere i n d e t a i l ( 8 ) . Lymphocyto tox ic i ty of the a n t i -
s e r a was a s s e s s e d in a t r y p a n b lue e x c l u s i o n a s s a y , w i th PVG/c 
s p l e e n c e l l s and r a b b i t complement ( 9 ) . 
H i s t o l o g i c examina t ion of t he g r a f t s . For t h i s purpose s k i n g r a f t s 
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and surrounding recipient skin were removed at different times 
after the i.V. injection of MARG and fixed in 4% buffered forma-
lin. From paraffin embedded tissue blocks 4 ym sections were cut, 
and stained with hematoxylin and eosin, with elastic van Gieson 
stain to visualize the vessel walls, and with Mallory's phospho-
tungistic acid hematoxylin stain to detect fibrin. The histologi-
cal sections were studied by the pathologist (M.J. B.) who had 
no knowledge of the experimental protocol used. At each tirae-
interval three grafts were studied, and all experiments were per-
formed twice. 
RESULTS 
Complement consumption du r ing g r a f t r e j e c t i o n . Mice were b l e d 
from the r e t r o - o r b i t a l ve in a t v a r i o u s i n t e r v a l s a f t e r the i n -
time after ¡.v. injection 
0 1 2 8 24 48 72 (hr) 
I 1 1 1 — I — ¡ — г - " — ι — " — ι — " — ι 1 1 1 
'U c h a n g e 
CH50 titer
 T 
.20 
О 
,20-
-40 
.60-
-80-
-100-
Fig. 1. Changes of CHSO titer in CS7BL6 -n.ale mice during the resection of a 
P'/G/a skin graft induced by the i.V. administration of 0.25 ml mouse 
anti rat serum (ш). Control experiments: CHSO titers in C57BL6 mice 
carrying a FVG/a skin graft (o), and in CS7B16 nice without a skin 
graft that received 0.2S ml mouse anti rat serum (·). Each point is 
the mean + S.E.M. of determinations in 8 mice. All determinations were 
done in triplicate. 
124 
jection of MARS, and hemolytic complement activity was measured 
in these sera. The results are given in Fig. 1. Two control ex­
periments were performed. One group of mice that received MARS 
but did not carry a graft, showed no changes in complement levels, 
The second group was grafted and treated with RAMLS but did not 
receive MARS. This treatment induced a 40% decrease of the CH50 
titer on day 7, with a gradual rise to normal values on day 9. 
The injection of MARS in mice carrying a PVG/c graft resulted in 
an immediate decrease of the CH50 titer. After 24 h when the 
graft was completely rejected, the CH50 titer returned towards 
normal values. These results show that there was consumption of 
complement during AAR. 
Influence of treatment with anticomplementary agents on hemolytic 
complement activity and AAR. C57BL6 male mice received three i.p. 
injections of 0.5 mg pentamidine, 2 mg carrageenin, 2.5 mg flu-
-4Θ -Z4 О 
t ime after i.p. injection 
anticomplementary agent 
72 9 6 (hr) 
- i 
% change 
CH50 t i t e r 
*
2 0 1 
- 2 0 
- 4 0 
-60 
- 8 0 
-ίσο 
Fig, 2. Changes of the CHSO titer in CS7BL6 mice after three i, p. administra­
tions (-48 h, -24 h, and 0 h) of various antiaomplementary agents. 
• 0, S mg pentamidine 
m 2 mg aarrageenin 
a 2. 6 mg flufenamia aaid 
о 5 mg suramin 
Each point represents the mean + S.E.M. of determinations in four 
different miae. Each determination was performed in dupliaate. 
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ТЛВЬЕ I. Influenae of treatment with anti eomplenentary agents 
on AAR of PVG/a skin grafted onto CS7BL6 recipients 
Group number Anticomplementary agent Occurrence of AAR 
1 none 19/19 
2 pentamidine (0.5 mg) Β/θ 
3 carrageenin (2 mg) 9/9 
4 flufenamic acid (2.5 mg) 8/8 
5 suramin (5 ng) 5/7 
a) injected i.p. 48, 24, and 2 h before the i.v. injection of HARG, on day 7 
(daily dose listed in ng) 
b) AAR was induced by i.v. injection of 0.1 ml MARG on day 7 after grafting 
c) number of mice with complete graft necrosis within 24-72 h after IIARG 
injection/number of mice tested 
fenamic acid, or 5 mg suramin at 24 h intervals. The CH50 titers 
measured 24, 48, 72 and 96 h after the third gift are presented 
in Fig. 2. Only with suramin a substantial decrease in CH50 titer 
was found. C57BL6 mice carrying a PVG/c graft received a similar 
treatment with these anticomplementary agents at 48, 24, and 2 h 
before the injection of 0.1 ml MARG on day 7. 
Table I shows that AAR was not prevented by pretreatment with pen-
tamidine, flufenamic acid, or carrageenin, which were the drugs 
that scarcely influenced the CH5Û titer. Suramin that induced a 
substantial depletion of hemolytic activity of complement pre-
vented AAR in 2 out of 7 mice. 
Influence of CoVF treatment on hemolytic complement activity. 
Prior to the experiments in which it was tried to inhibit AAR with 
CoVF we studied the effects of increasing CoVF dosages on comple-
ment activity in otherwise untreated C57BL6 mice. Fig. 3 shows 
that, 24 h after a dose of 20 U, hemolytic activity had almost 
time after i.p. injection of CoVF 
72 96 120 (hr) 
-100 
Fig. 3. Influence of CoVF treatment on the CH50 titer of С57БЬв mice. 
• single dose of 2.S U i.p. 
a single dose of 5 U i.p. 
m single dose of 20 U i.p. 
о daily dose of 20 U i.p. 
Each point represents the mean * S.E.M. of determinations in four 
different mice. Each determination uas performed in triplioate. 
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TABLE I I . Influenae of CoVF treatnent on AAR of P/G/o 
skin grafted onto СБ7вІв геаг^гепЬв 
Group number Dose MARC (nl) CoVF treatment a) Occurrence of AAR 
0.1 ml 
0.1 ml 
0.25 ml 
0.5 ml 
0/15 (MST: 23.0) 
19/19 
0/8 
6/11 
10/10 
d) 
a) 20 U CoVF daily i.p., started on day 5 after grafting and continued for 7 days or 
until rejection of the graft was complete 
b) AAR was induced by i.v. injection of listed volumes of MARG on day 7 after grafting 
c) number of mice with complete graft necrosis within 24-72 h after MARG injection/ 
number of mice tested 
d) MST = median survival time 
dropped to zero. Daily injections of this dose ensured a complete 
depletion of hemolytic complement activity during at least 5 days. 
Influence of CoVF treatment on AAR in normal and C5 deficient mice. 
C5 7BL6 mice carrying PVG/c skin grafts were treated with daily 
injections of 20 U CoVF from day 5 after transplantation. Injection 
of 0.1 ml MARG at day 7 did not induce AAR, while such a dose 
induced rapid destruction in recipients with a normal complement 
status (Table II). However, the grafts in CoVF treated recipients 
were not completely protected against the destructive effects of 
the anti rat serum since at higher doses AAR occurred. A dose of 
0.25 ml destroyed the grafts in about half of the recipients, 
while 0.5 ml MARG induced AAR in 100% of the cases. Since complete 
and sustained loss of hemolytic complement activity had been in-
duced by CoVF treatment, these results suggested that graft des-
truction could be mediated through complement independent mecha-
nisms. More arguments for this assumption were sought by performing 
similar experiments in C5 deficient mice. The results are shown 
in Table III. Similarly to the findings in CoVF treated mice, 0.1 
ml MARG did not induce AAR in these animals. With increasing 
doses of MARG the grafts again became sensitive to the antibody. 
That AAR in these animals only occurred at higher antibody doses 
was apparently a consequence of the C5 deficiency since 0.1 ml 
MARG injected along with 0.5 ml of non complement deficient nor-
mal mouse serum induced AAR in all recipients (group 5). The 
results in these C5 deficient mice confirm the findings of Winn 
et al (4). He presumed that in these animals activation of C3 
was sufficient to induce destruction and that, although activa-
tion of lytic components of complement contributed to the damage, 
these were not essential. If this were the case, one would expect 
that C3 depletion in C5 deficient mice would further decrease the 
sensitivity of the grafts to AAR, or would even protect them 
completely against destruction. Therefore we treated DBA/2 mice 
with a protocol identical to that used in the mice that had no 
genetic complement deficiency. The results given in Table III 
(groups 6 and 7) show that this CoVF treatment caused no sub-
stantial change in the sensitivity to MARG. 
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TABLE III. Influence of Ci deficiency and CoVF treatment on AAR 
of PVG/c skin grafted onto DBA/I reaipients 
Group number Dose MARG (nl) CoVF treatment Occurrence of AAR 
1 - - 0/15C) (HST: 24.5) 
2 0.1 ni - 0/16 
3 0.25 ml - 10/17 
4 0.5 ml - 11/11 
5 0.1 ml + 0.5 nl NMSd) - 10/10 
6 0.25 ml + 2/7 
7 0.5 nl + 9/9 
a) 20 U CoVF daily i.p., started on day 5 after grafting, and continued for 7 days or 
until rejection was complete 
b) AAR was induced by i.v. infection of the listed volumes of MARG on day 7 after grafting 
c) number of mice with complete graft necrosis within 24-72 h after MARG injection/ 
number of mice tested 
d) NHS = normal mouse serum not deficient in C5# injected along with MARG 
Destructive activity of non-complement fixing IgGl subclass anti-
bodies . We surmised that non-complament fixing antibodies could 
also cause AAR if complement independent mechanisms indeed played 
a role in our system. For this purpose we tested the activity of 
purified IgGl antibodies prepared from MARG. As stated in the 
methods the preparation was slightly contaminated with IgG2. If 
tested in a cytotoxic assay against PVG/c lymphocytes residual 
complement dependent cytotoxicity was found resulting in 50% cell 
lysis up to a dilution of 1:8. This was attributed to the conta-
minating IgG2, present in a concentration of 6.5 ug/ml. The ori-
ginal MARG pool contained 6 ,900 pg IgG2/ml and had a cytotoxic 
titer of 1:20,480. The destructive effects of increasing doses 
of IgGl were studied in C57BL6 recipients with a normal complement 
status (Table IV). The limiting dose for the induction of AAR was 
approximately 800 pg IgGl. This dose was contaminated with 0.4 
yg of IgG2. From the results of the dose response study for IgG2, 
also presented in Table IV, it can be seen that the amount of 
IgG2 contamination of the IgGl preparation cannot be held res-
ponsible for the destruction, since the limiting dose for IgG2 is 
between 65 and 131 yg and thus at least 160 times higher. 
Histology of AAR in mice with a normal complement status and in 
complement depleted animals. Induction of AAR in complement de-
ficient animals did not only require higher amounts of antibodies 
but the grafts also showed a different rejection pattern. In mice 
with a normal complement status there was rapid necrosis of the 
graft that was complete in 8 to 24 h. In C3 or C5 deficient 
animals the process occurred more slowly. It started with hyper-
aemia of the graft followed by cyanosis and necrosis that was 
complete after 48-72 h. The histological findings reflected these 
macroscopic differences. Grafts, that were carried by mice with 
a normal complement status, showed intravascular coagulation with 
damage of vessel walls and extravasation of erythrocytes at 30 
min after the injection of 0.25 ml of MARG. There was no intra-
vascular increase of PMN. Necrosis was found after 2 h and was 
complete after 8 h. In grafts of mice in which C3-depletion was 
induced by CoVF, the first event was a dense intravascular accu-
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TABLE IV. AAR of FVG/o skin grafted onto CS7BL6 recipients induced by the administration of 
IgGl and IgG?, subclass antibodies specifically directed against the donor antigens 
Preparation IgGl (pg) IgG2 (pg) Occurrence of AAR a) 
IgGl 
1625 
812 
406 
0.Э 
0.4 
0.2 
5/5" 
2/6 
0/5 
IgG2 
0.3 
0.2 
0.1 
261 
131 
65 
5/5 
5/5 
0/5 
a) AAR was induced by i.v. injection of the listed amounts of IgGl or IgG2 on day 7 after 
grafting 
b) nunber of nice with complete graft necrosis within 24-72 h after the IgGl or IgG2 
injection/nunber of mice tested 
mulation of PMN at one half and two hours after the injection of 
0.25 ml of MARG. There were no signs of intravascular coagulation 
at that time. Slight vessel damage with incipient extravasation 
of erythrocytes and intravascular coagulation started at 8 h. 
Partial or complete necrosis was present at 36 and 48 h after the 
injection. The accumulation of PMN was not caused by the CoVF 
treatment since sections of normal skin of the same recipient, 
and grafts in mice that were treated with CoVF but not with MARG 
showed no increase of PMN. These results show that dependent on 
the complement status of the recipients two distinct types of 
antibody mediated graft destruction occur. 
DISCUSSION 
It is clear from this and previous studies (2-4,9) of anti-
body mediated rejection, that in recipients with a normal comple-
ment status, activation of complement is an important effector 
system that leads to graft damage. The decrease of the CH50 titers 
during AAR of PVG/c skin grafts indicates that complement con-
sumption took place. The CH50 titer remained depressed until re-
jection was complete. Similar results have been reported during 
rejection of xenogeneic kidneys in dogs (10). 
An in vitro anticomplementary effect has been described for 
pentamidine (11-15), flufenamic acid (16) and carrageenin (17,18), 
but we were not able to induce in vivo complement depletion with 
these drugs. With respect to carrageenin it has been reported 
earlier that its anticomplementary activity in vivo is not very 
impressive (19) . Only treatment with suramin induced a substantial 
decrease of the CH50 titer in vivo that was in line with its 
reported anticomplementary activity in vitro (20,21). The residual 
complement activity was obviously sufficient to induce graft des-
truction, since only 2 out of 7 grafts were protected against the 
destructive effect of a relatively low dose (0.1 ml) of MARG. 
Only with long lasting depletion of complement activity by CoVF 
protection against 0.1 ml of MARG was obtained. However, when the 
dose was raised to 0.5 ml, destruction of all grafts again occurred, 
although the reaction was not as abrupt as seen in animals with 
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a normal compleirent status. It is possible that traces of comple­
ment activity not measurable in the hemolytic complement assay 
in vitro, mediated the destruction at higher doses of antibody. 
Two findings argue against this explanation. First, in C5 defi­
cient animals the decrease in sensitivity was similar to that in 
C3 depleted animals and there was no further drop when these ani­
mals were also treated with CoVF. One would anticipate a decrease 
to occur if C3 activation, without activation of terminal comple­
ment components, played an important role in the destruction. 
A second and stronger argument for the involvement of complement 
independent mechanisms, was our finding that non-complement 
fixing IgGl antibodies also caused destruction. This destructive 
effect of non complement fixing IgGl is not present in all systems. 
We have previously shown that mouse skin allografts that can be 
destroyed by administration of specific alloantiserum together 
with rabbit complement, are completely unaffected if IgGl anti­
bodies are used (7). These studies were performed in a congenie 
model with limited antigenic differences and this suggests that 
the occurrence of destruction by IgGl depends on the antigenic 
disparity of the donor-recipient combination. Λ further argument 
for the fact that complement-independent mechanisms can only 
become operative in graft models with a wide antigenic disparity, 
is our previous finding that AAR of mouse allografts only occurred 
in the presence of a completely intact complement system (3). 
Histologic studies can give insight into the spectrum of 
reactions that may lead to antibody mediated vascular damage. The 
results in animals with a normal complement status show that acute 
intravascular coagulation can occur, without involvement of PMN. 
It is likely that under these circumstances there is direct cyto-
lysis of vascular endothelium by antibody and complement with 
consequent rapid platelet aggregation and coagulation. This has 
happened before PMN, attracted by activated chemotactic factors, 
can reach the graft. It, thus, seems that PMN are not absolutely 
necessary to cause graft destruction initiated by antibody. The 
destruction can, however, also take place via a classic Arthus 
type reaction with activation of chemotactic complement compo­
nents and secondary attraction of PMN. We have shown previously 
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that this type of reaction occurs in an allogeneic system, where 
destruction is seen only in the presence of exogenous complement 
(2). After accumulation of PMN in the graft vessels, there is 
vascular damage, extravasation of erythrocytes and necrosis. Sim-
ilar histologic changes have been found in another model of anti-
body mediated destruction of rat skin grafts (1,4). On the basis 
of our findings we propose that a third pathway of vascular damage 
should be added to this spectrum. Although this pathway is comple-
ment independent it is mediated by PMN as shown by the histologic 
studies in animals depleted of complement by treatment with CoVF. 
It is not clear which factors are responsible for the attraction 
of PMN under these circumstances. It might be the result of immune 
adherence of PMN to the Fc part of the immunoglobulins bound to 
the vascular endothelium (22). Since there is no amplification of 
this process by the generation of chemotactic factors of the com-
plement system, the reaction develops more slowly and requires a 
relatively high amount of antibodies. This does not exclude that 
the process is amplified by other mechanisms. It has been shown 
that mouse IgG antibodies can induce a complement independent 
release of histamin and serotonin from leukocytes (23), and this 
could obviously contribute to the rejection process. Furthermore, 
immune adherence of PMN can cause release of lysosomal enzymes 
(22), that can enhance further accumulation of PMN, causing damage 
of the vascular endothelium (24). Elucidation of the mechanism in 
this type of rejection clearly requires further study. Our findings 
are in apparent contrast to earlier observations in reversed pas-
sive Arthus reactions and in experimental nephrotoxic nephritis, 
where depletion of the complement system could prevent PMN accu-
mulation (25-29). This stresses the fact that in graft rejection 
other mechanisms can become operative, whose activation is proba-
bly influenced by the extent of antigenic disparity that exists 
between donor and recipient. 
The existence of this mechanism might have practical implica-
tions for clinical transplantation. Attempts to influence humoral 
graft rejection by complement depletion might fail because this 
approach does not provide absolute protection against antibody 
mediated graft destruction. 
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SUMMARY 
Complement dependency of acute antibody mediated rejection 
(AAR) was studied in a xenogeneic skin graft model in the mouse. 
PVG/c rat skin grafted to immunosuppressed mice is quickly des-
troyed by intravenous administered mouse anti rat serum on day 7 
after grafting. We demonstrated depression of the CH50 titer in 
the recipients, indicative for complement consumption during the 
rejection process. Of four anticomplementary agents: pentamidine, 
carrageemn, flufenamic acid and suramin, only treatment with 
suramin led to a substantial complement depletion in vivo. 
Administration of suramin prior to anti rat serum protected 30% 
of the grafts against AAR, while the three other drugs were in-
effective in this regard. Complete and long lasting complement 
depletion induced by treatment with cobra venom factor (CoVF) 
decreased the sensitivity of the grafts for AAR. However, complete 
protection was not achieved, since high doses of anti donor serum 
again induced destruction. Similar results were obtained in C5 
deficient recipients, and m CoVF treated C5 deficient recipients. 
These results indicated that complement independent rejection 
mechanisms were operative. This was further substantiated by the 
finding that pure non-complement fixing IgGl subclass antibodies 
were able to elicite AAR. Histologic studies showed that AAR of 
grafts in mice with a normal complement status was caused by 
intravascular coagulation without primary involvement of poly-
morphonuclear leukocytes. In complement depleted animals an 
Arthus-like reaction was seen, with dense intravascular accumula-
tion of PMN, that, apparently, were attracted to the graft through 
complement independent mechanisms. 
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Chapter Vili 
SUMMARY 
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Rejection mediated by antibodies accounts for a considerable 
amount of graft losses in renal transplantation. The detrimental 
effects of antibodies that are already circulating at the time of 
grafting or that are formed after transplantation might be di-
minished by interfering with the effector systems triggered by 
these antibodies. Of these effector systems the complement system 
is one of the most important, and an understanding of its precise 
role in antibody mediated rejection (AAR) might provide additional 
tools for the management of the rejection process. The aim of 
this study was to investigate the role of the complement system 
in AAR in an experimental animal model. 
A protocol was used in which graft destruction could reproduci-
bly be elicited by the passive administration of anti donor anti-
serum to skin graft recipients, whose cellular immune response 
was suppressed by treatment with anti mouse lymphocyte serum. 
The first set of experiments was performed in an allogeneic skin 
graft model in the mouse. In this model administration of exogenous 
complement together with antiserum is required for AAR, since the 
recipient's endogenous complement system is inefficiently activa-
ted by mouse alloantisera. 
The influence of antigenic disparity on AAR was studied in nine 
donor-host combinations whose histoincompatibility ranged from a 
single non-H-2 difference to a disparity for the complete H-2 
complex plus multiple non-H-2 differences. With the exception of 
combinations with a single or few non-H-2 differences AAR could 
be induced in all combinations. It was found that with increasing 
histoincompatibility, the amount of antibodies required for the 
induction of AAR decreased, parallel to the decrease of the median 
survival time of skin grafts in untreated animals, and also paral-
lel to the increase of the cytotoxic titer of the anti donor serum 
in vitro. It is concluded that the results for immunogenicity of 
the different histocompatibility loci as described for cell-mediated 
rejection, also apply to our model of humoral graft destruction. 
Complements from various species differ in their effectiveness 
in in vitro lymphocytotoxicity tests with mouse alloantisera. All 
antisera, when tested with rabbit complement (RC), gave rise to a 
higher cytotoxic titer than with guinea pig complement (GPC) or 
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human complement (HC). These differences in effectivity were 
mirrored in the in vivo studies. In some donor-host combinations 
with relatively small antigenic disparity (multiple non-H-2 dif-
ferences, H-2D or H-2K) , where AAR could be elicited by injection 
of RC along with anti donor serum, GPC and HC were ineffective. 
In the combinations with a greater histo-incompatibility (H-2D 
plus non-H-2, H-2K plus non-H-2, H-2 and H-2 plus non-H-2) GPC 
and HC were also effective. However, dose response studies showed 
that GPC was less efficient than RC, for a greater amount of anti-
serum was necessary to induce AAR with it. In none of the allo-
geneic donor-host combinations were we able to induce AAR by in-
jection of antiserum alone. This is in agreement with the fact 
that mouse complement never caused lymphocytotoxicity of target 
cells in vitro, not even with the strongest antiserum. In general 
terms one can conclude that the cytotoxic titer of an antiseruir. 
as tested in vitro gives a good indication about its destructive 
power in vivo. 
The question whether all components of the complement system 
are necessary for the induction of AAR was studied in an allo-
graft model in which a complete H-2 disparity existed between 
donor and recipient (B10.D2 -* C57BL6). As stated above AAR can be 
evoked in such a combination by injection of anti donor serum 
along with RC, GPC or HC. Experiments were done in which allo-
antiserum was injected together with sera from animals deficient 
in single complement factors or, alternatively, with sera that 
were artificially depleted of one of the complement components 
(R-sera). The in vivo effects of the various R sera were again 
compared with their in vitro activity in the lymphocytotoxicity 
assay. None of the R-sera (Rl, R4, R3, R6 or R9) was able to 
mediate lymphocytotoxicity when tested with B10.D2 target cells 
and C57BL6 anti B10.D2 serum. Reconstitution with the deficient 
complement factor restored the lymphocytotoxic capacity of all 
the R sera. If normal mouse serum was added to Rl and R9 serum, 
these regained their cytotoxicity, demonstrating that mouse CI 
and C9 could replace the deficient factor. For CI this was further 
substantiated by the finding that a crude mouse CI preparation 
had the same restoring effect on Rl serum as whole mouse serum. 
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The R4, R3 and R6 sera could not be reconstituted with normal 
mouse serum. If the different R sera were injected with anti donor 
serum in C57BL6 recipients of a B10.D2 skin graft results analogous 
to the in vitro findings were obtained. Rl and R9 serum induced 
AAR without prior reconstitution. On the other hand C4, C3 and C6 
depleted complement sources did not evoke AAR. This was only 
obtained if, prior to administration, these R sera were reconsti-
tuted with the appropriate complement factor. These experiments 
permit the following conclusions. The close correlation between 
the in vivo activity and the cytotoxicity in vitro strongly sug-
gests that activation of the classical complement pathway is 
necessary to induce AAR in this allogeneic model. This is corro-
borated by the finding that R4 serum, which can be activated nor-
mally via the alternative pathway, did not elicit AAR. Furthermore, 
the complete complement sequence has to become activated in this 
model. Generation of chemotactic complement factors (C3a and C5a) 
alone, is not sufficient to cause AAR, since R6 serum, that can 
generate normal chemotactic activity, did not induce AAR. Lastly, 
the low cytotoxic properties of mouse complement do not reside 
in factors CI and C9, because these factors could effectively 
restore Rl and R9 serum. 
The aim of the second set of experiments was to elucidate the 
role of endogenous complement in AAR. For this purpose a xeno-
geneic skin graft model was used in which a PVG/c rat skin graft 
was placed on immunosuppressed C57BL6 or DBA/2 mice. In this model 
of greater antigenic disparity administration of exogenous comple-
ment is not required and the injection of mouse anti rat serum 
alone causes a rapid and violent destruction. Complement consump-
tion was measured during AAR, and complement dependency of the 
destruction was studied by using complement depleted recipients 
and by the administration of non-complement fixing antibodies. 
Before this study was undertaken a sensitive assay of mouse 
complement had to be developed in order to measure complement con-
sumption and complement inhibition. Because under test conditions 
normally used for the measurement of hemolytic activity of human 
and guinea pig complement no activity is found with mouse comple-
ment, several conditions of the test were investigated to increase 
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its sensitivity. It was found that 7S IgGl amboceptor activated 
mouse complement better than 19S IgM amboceptor. The use of a 
Cr release assay allowed the reduction of the number of target 
cells. Furthermore it was found that optimal incubation conditions 
were: an ionic strength of the incubation medium of 0.13 M NaCl, 
an incubation time of 90 minutes, and an incubation temperature 
of 30 C. With this test it was possible to measure hemolytic ac-
tivity of mouse complement sensitively and reproducibly. 
With the above mentioned method we found complement consumption 
during AAR of a PVG/c skin graft carried by C57BL6 recipients. 
Ten minutes after the i.v. injection of mouse anti rat serum there 
was a sharp decrease in CH50 titer, which remained depressed during 
the rejection process. After the rejection had been completed the 
CH50 titer gradually rose to normal levels. Subsequently, attempts 
were made to inhibit complement activity and to prevent AAR with 
four agents which are anticomplementary in vitro. With pentamidine, 
carrageenin and flufenamic acid no significant decrease of the 
complement activity in C57BL6 mice was obtained. Treatment of 
these agents did not prevent the occurrence of AAR. Although ad-
ministration of suramin caused a substantial decrease in CH50 titer 
(20% of normal values), it protected only 2 of 7 grafts against 
AAR. Prevention of AAR was only found if a complete and prolonged 
depletion of the complement system of the C57BL6 recipient was 
induced by treatment of CoVF prior to the administration of anti 
donor serum. Similar results were obtained in C5 deficient DBA/2 
recipients. The protective effect of CoVF pretreatment or of C5 
deficiency, was, however, overcome if a greater dose of mouse anti 
rat globulin (MARG) was given to the recipients. This was even the 
case if C5 deficient recipients were also treated with CoVF. 
With 0.5 ml MARG, AAR was obtained in all recipients despite C3 
depletion, C5 deficiency, or C3 depletion plus C5 deficiency. 
These results indicated that complement independent mechanisms 
became operative in this xenogeneic skin graft model, provided 
sufficient amounts of antibody were presented to the graft. 
A further argument for this was obtained by the finding that non-
complement fixing IgGl antibodies, prepared from MARG, could in-
duce AAR. Although it is as yet not clear which mechanisms are 
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operative in the complement independent destruction, we have 
acquired some clues from histologic examinations of the grafts. 
In animals with a normal complement status the destruction of the 
xenografts was brought about by acute intravascular coagulation 
without primary involvement of polymorphonuclear leukocytes (PMN). 
Xenografts rejected by complement depleted recipients showed 
dense intravascular accumulation of PMN, with only secondary signs 
of intravascular coagulation. These PMN must have been brought 
into the graft by complement-independent mechanisms. This is 
possibly the result of immune adherence of PMN to the Fc part of 
the antibodies bound to the vascular endothelium. Elucidation of 
the mechanisms in this type of rejection clearly requires further 
s t udy. 
When extrapolating these results to the clinical transplanta-
tion situation, one may conclude that it is worthwile to continue 
the search for effective anticomplementary agents, since these 
might lead to attenuation of the humoral rejection process. 
Agents that inhibit the complement components of the classical 
activation unit are preferable, because they have the advantage 
of leaving the alternative pathway intact. This is important for 
the complement dependent defense mechanisms against bacteria. 
Whether complement independent mechanisms can become operative in 
the vascular rejection of human kidney grafts remains speculative, 
until we know more about the role of immunoglobulin subclasses 
and about the extent of antigenic disparity necessary to initiate 
this process. 
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De regels voor de immunogeniciteit van de diverse loci binnen het 
H-2 complex gelden niet alleen voor de cellulaire maar ook voor de 
humorale afstoting van huidtransplantaten. 
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Acute antilichaam afhankelijke afstoting van allogene huidtrans-
plantaten in de muis vereist een aktivatie van de volledige 
klassieke route van het complement systeem. 
3 
Acute antilichaam afhankelijke afstoting van xenogene huidtrans-
plantaten in de muis kan via complement onafhankelijke mechanismen 
verlopen. 
4 
Transplantaatbeschadiging door antilichamen kan zowel het gevolg 
zijn van een lokale Shwartzman reactie als van een klassieke 
Arthus reactie. Welke van de twee tot ontwikkeling zal komen hangt 
af van het antigene verschil tussen donor en ontvanger, en van de 
titer en subklas specificiteit van de circulerende antilichamen. 
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In tegenstelling tot allogene niertransplantaties bij het konijn, 
induceert Cyclosporine A geen blijvende tolerantie bij muizen die 
een allogeen huidtransplantaat dragen. 
- S.P.M. Lems en R.A.P. Koene (1979) 
ter publicatie aangeboden 
- C.J. Green en A.C. Allison 
Lancet (1978) , 1, 1182 
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Bij een patient met een niet-purulente mono- of oligoarthritis 
dient men ook een Campylobacter jejuni infectie als mogelijke 
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- J.H.H. Berden, H.L. Muytjens en L.B.A. v.d. Putte 
British Medical Journal (1979), !_, 380 
7 
Immuuncomplexen en complement aktivatie spelen een belangrijke 
rol bij de ontwikkeling van de complicaties van een Plasmodium 
falciparum infectie. 
- WHO Technical Report (1975) 579 
- eigen waarneming 
8 
Bij een onbegrepen acute nierinsufficientie moet als mogelijke 
oorzaak de ziekte van McArdle (niet-traumatische rhabdomyolyse) 
overwogen worden. 
- eigen waarneming 
9 
Er zijn voldoende aanwijzingen voor een immunologische Pathogenese 
van multiple sclerose om goed opgezette pogingen ter behandeling 
van deze ziekte met immunosuppressiva te rechtvaardigen. 
- P. Delmotte, O.R. Hommes en R. Gonsette (redacteuren) 
Immunosuppressive treatment in multiple sclerosis. 
European Press, Gent, 1977 
10 
In een toekomst ige t r a n s p l a n t a t i e wetgeving v e r d i e n t t en a a n z i e n 
van d o n a t i e van organen h e t "geen-bezwaar-sys teem" de voorkeur 
boven h e t " toesternmingssysteem" . 
- H.J.J. Leenen 
Nederlands Juristen Blad (1978) , 53_, 871 
11 
Het onderwijs in de medische geschiedenis verdient een ruimere 
plaats in de medische opleiding. 
Nijmegen, 27 april 19 79 J.H.M. Berden 



